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1 INTRODUCTION
1 Introduction
1.1 The triple A syndrome and the adrenal gland function
The triple A syndrome (MIM #231550) is an autosomal recessive disease manifesting with
the triad of adrenocorticotropic hormone (ACTH)-resistant adrenal insufficiency, achalasia of
the stomach cardia and impaired tear production (alacrima) in combination with progressive
neurological impairment of the central, peripheral and autonomic nervous systems (Allgrove et
al., 1978; Grant et al., 1992). Patients suffer from heterogeneous neurological symptoms fea-
turing neurodegeneration, cerebellar ataxia, peripheral neuropathy with consecutive weakness
of preferably distal muscles and mild mental retardation (Tullio-Pelet et al., 2000; Handschug et
al., 2001). Adrenal insufficiency may appear later in life than achalasia and alacrima and may
develop gradually (Milenkovic et al., 2010).
The adrenal gland consists of two endocrine distinct tissues: the steroid hormone-producing
adrenal cortex and the medulla where chromaffin cells synthesise catecholamines. However, it
is known that this view is too simplified and the distribution of the different cell types is not as
distinct as firstly thought (Ehrhart-Bornstein et al., 1998). The two tissues originate from different
embryonal lineages. During embryogenesis the adrenal primordium consists of mesoderm-
derived cells which develop into adrenocortical cells.
The mammalian adrenal cortex consists of three distinct zones depending on morphology
and type of steroid synthesis. Cells of the zona glomerulosa synthesise the unique miner-
alocorticoid aldosterone, zona fasciculata is the production site for glucocorticoids and cells
of the zona reticularis produce androgens (sex steroids) (Figure 1) (Ehrhart-Bornstein et al.,
1998). The enzymes, responsible for the steroid synthesis in all three zones, reside either in
mitochondria (type I) or in the ER (type II). These enzymes are cytochrome P450 enzymes
(CYP P450s) (nomenclature for these enzymes: CYP followed by a number for the gene fam-
ily, a capital letter for the gene sub-family and a second number for the specific gene, e.g.
CYP17A1). These enzymes produce steroids with the help of a heme prosthetic group in a
redox reaction involving NADPH and molecular oxygen (Pandey and Fluck, 2013; Nelson,
2009). The chemical reaction steps are explained in detail in subsection 1.3 Oxidative stress.
Chromaffin cells in the adrenal medulla originate form ectodermal precursor cells which
immigrate in the adrenal “Anlagen” where they develop into medullary cells under the influence
of the adrenocortex (Pohorecky and Wurtman, 1971; Axelrod and Reisine, 1984). In these
chromaffin cells catecholamines (in particular epinephrine and nor-epinephrine), transmitters,
neuropeptides and other proteins are produced (Winkler et al., 1986). In my thesis the work is
focussed on the adrenal cortex.
Ehrhart-Bornstein et al. discussed the possible interaction between adrenal cortex and
medulla in detail and it is shown that the different cells in the adrenal communicate with each
other in a cortical-medullary fashion (Ehrhart-Bornstein et al., 1998). Moreover, the adreno-
cortical function is regulated by a variety of external and internal stimuli: the internal cortical-
medullary communication, external vascular supply and neural innervation, the immune sys-
tem, internal and external produced growth factors, the renin-angiotensin II and corticotropin-
releasing hormone (CRH)-ACTH systems.
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Figure 1 – Overview of adrenal steroidogenesis.
The genes coding for enzymes are written in italic typeface (olive). All enzymes are microsomal enzymes, despite the mitochondrial
CYP11A1, CYP11B1 and CYP11B2. CYP17A1 has hydroxylase and lyase activity. The zona glomerulosa mainly produces
mineralocorticoids (blue), zona fasciculata is responsible for production of glucocorticoids (orange) and androgens are made in
zona reticularis (pink). Stimulation by adrenocorticotropic hormone (ACTH) leads to the initiation of steroidogenesis by facilitating
the import of cholesterol from the liver into the mitochondria of adrenocortical cells with the help of steroidogenic acute regulatory
protein (StAR) in the outer mitochondrial membrane (Han et al., 2014).
The release of glucocorticoids in the adrenal zona fasciculata is primarily regulated by the
hypothalamus-pituitary-adrenal axis by its secretagogues CRH, ACTH and adiuretin and a ne-
gative cortisol-related feedback loop. Briefly, stimulation of the seven transmembraneG-protein-
coupled ACTH receptor (melanocortin 2 receptor (MC2R)) by stress-induced high ACTH levels
leads to cAMP increase by adenylate cyclase and protein kinase A activation resulting in ge-
nomic (e.g. through the transcription factor SF1) and non-genomic (e.g. phosphorylation) re-
sponses (Figure 2). Since ACTH can partly stimulate mineralocorticoid synthesis, production of
glucocorticoids leads to the inhibition of aldosterone production in a negative feedback through
corticosterone (Clark and Weber, 1998).
The secretion of aldosterone in the adrenal zona glomerulosa is primarily dependent on
the plasma renin-angiotensin II system. Glomerulosa cells express high amounts of G-protein-
coupled angiotensin 1 receptor compared to the other two zonae. Thus, innervation by an-
giotensin II is highly cell type-specific. Shortly, the pathway is regulated by the inositol triphos-
phate/ diacylglycerole pathway leading to calcium release from the ER and activation of protein
kinase C which in turn activates expression of genes responsible for aldosterone synthesis.
Triple A syndrome patients suffer from ACTH-resistant adrenal insufficiency. Glucocorticoid
and androgen production is most frequently affected in these patients and about 15-25 % of
triple A patients show a deficiency in mineralocorticoid production (Clark and Weber, 1998;
Tsigos, 1999; Lanes et al., 1980) (unpublished data). This may be explained by the cellular
degeneration seen in histological sections of adrenal glands of triple A syndrome patients: in
both, zona fasciculata and zona reticularis hormonal active cells are displaced by nondescript
2
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Figure 2 – Second messenger pathways after adrenocorticotropic hormone stimulation in adrenal fas-
ciculata cells.
Adrenocorticotropic hormone (ACTH) binds to its seven-transmembrane G-protein-coupled receptor which leads to the activation
of the Gsα-subunit by GTP and separation of the βγ-subunits. The Gsα-subunit activates the membrane-associated adenylate
cyclase and cAMP is produced. cAMP activates PKA and its catalytic subunits (C) consecutively phosphorylate a row of sub-
strates including cAMP-response-element-binding-protein (CREB) and SF1 (not shown here). This activation leads to initiation of
glucocorticoid synthesis through steroidogenic acute regulatory protein (StAR) (Clark and Weber, 1998).
cells. In contrast, zona glomerulosa is almost normally developed and seems to escape cell
degeneration (Figure 3) (Allgrove et al., 1978; Clark and Weber, 1998).
Figure 3 – Histology of the adrenal cortex of a child who died from non-endocrine manifestations (A)
and two children who died from triple A syndrome (B).
Zona glomerulosa (marked with the grey box G) is preserved in all patients but zona fasciculata (F) and reticularis (R) are displaced
by atypical nondescript cells (Clark and Weber, 1998, modified).
Mutations in the AAAS (achalasia-adrenal insufficiency-alacrima syndrome) gene cause
triple A syndrome. AAAS encodes the protein ALADIN (alacrima-achalasia-adrenal insuffi-
ciency neurologic disorder) (Tullio-Pelet et al., 2000; Handschug et al., 2001; Huebner et al.,
2002). ALADIN is ubiquitously expressed but shows enhanced levels in neuroendocrine and
gastrointestinal structures; tissues which are most affected in triple A patients implying a cell
type-specific function of ALADIN (Handschug et al., 2001). In order to develop an animal
model for human triple A syndrome, mice lacking a functional AAAS gene were developed.
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Knock-out mice showed a mild phenotype with normal hormone measurements and normal
adrenal histology. Surprisingly, no such adrenal phenotype seen in triple A patients has been
so far described in AAAS knock-out mice; probably, because mice predominantly have a zona
glomerulosa (Huebner et al., 2006). This underlines the assumption that ALADIN supports a
species-specific role in human cellular biology.
1.2 The nuclear pore complex
1.2.1 Structure and architecture
In 2002 ALADIN was identified as a component of the nuclear pore complex (NPC) (Cronshaw
et al., 2002). Eukaryotic NPCs are large protein complexes residing in the nuclear envelope
composed of ~30 different proteins, known as nucleoporins (NUPs), which mediate the trans-
port of macromolecules between the cytoplasm and the nucleus. The bi-directional transport
facilitates trafficking of proteins and RNA across the nuclear envelope (Fahrenkrog, 2014).
NPC structures and actions are highly specific and tightly regulated in eukaryotic cells.
NUPs assemble in repetitive sub-complexes to build NPCs (Lim et al., 2008; Maimon et al.,
2012; Bui et al., 2013; D’Angelo and Hetzer, 2008). It was analysed by scanning electron
microscopy and proteomic analyses that one NPC is actually formed of 500-1000 individual
proteins making up a total molecular weight of 110 MDa in vertebrates (Bui et al., 2013; Alber
et al., 2007). Most information about highly evolutionary conserved NPC structures has been
determined from isolated Xenopus laevis oocyte nuclei but also from yeast, amoebozoa, plants
and humans (Maimon et al., 2012; Bui et al., 2013; Frenkiel-Krispin et al., 2010; Kiseleva et al.,
2004; Fiserova et al., 2009; Beck et al., 2004; Capelson et al., 2010; Stoffler et al., 2003).
Briefly summarised, NPCs are built of a central framework (spoke-ring complex) aligned
with eight cytoplasmic filaments and a nuclear basket which is formed of eight filaments which
join in a distal ring (Figure 4). The central framework consists of eight spokes which form the
~40-45 nm central pore/channel (at the nuclear envelope mid plane) (Maimon et al., 2012; Bui
et al., 2013; Frenkiel-Krispin et al., 2010; Beck et al., 2004; Stoffler et al., 2003; Beck et al.,
2007; Pante and Kann, 2002). The channel facilitates the nucleo-cytoplasmic exchange of
molecules of maximal ~39 nm in a signal-, receptor- and energy-dependent fashion whereas
small molecules of about 9 nm can diffuse freely between the two cell compartments (Pante
and Kann, 2002; Enss et al., 2003; Mohr et al., 2009).
Figure 4 – Nuclear pore complex architecture.
Nuclear pore complex side view of Xenopus laevis oocyte nuclei visualised by transmission electronmicroscopy (left) and schematic
presentation of main structural components of the nuclear pore complex (right) (Fahrenkrog, 2014).
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The 30 different NUPs building the NPC structure are grouped in sub-complexes according
to their amino acid sequence and their predicted structural motifs (Figure 5) (Schwartz, 2005;
Devos et al., 2006). Transmembrane NUPs reside in the nuclear envelope and sit at the section
between central framework and pore membrane (e.g. NDC1). Scaffold NUPs are distinct in
their structural motifs as all contain α-helical solenoid and β-propeller fold motifs (e.g. NUP107-
160). The last group of NUPs can further sub-divided in NUPs of the cytoplasmic filaments
(e.g. NUP358), of the central channel (e.g. NUP62) and of the nuclear basket (e.g. NUP153).
All proteins of the last group contain characteristic phenylalanine-glycine (FG) rich repeats in-
terspersed with hydrophobic linkers and/or coiled-coil motifs (Fahrenkrog, 2014). FG repeats
have been shown to be essential for trafficking due to their affinity for transport receptors like
importin β (Suntharalingam and Wente, 2003).
Figure 5 – Grouping and localisation within the nuclear pore complex.
Depending on their amino acid sequence, structural motifs and localisation, nucleoporins (NUPs) can be divided into different
groups: transmembrane proteins (white), scaffold NUPs (light grey), NUPs of the cytoplasmic filaments (gradient), central channel
NUPs (middle grey) and nuclear basket NUPs (dark grey) (Fahrenkrog, 2014).
1.2.2 ALADIN as a scaffold nucleoporin
Cronshaw et al. identified ALADIN as a protein of the NPC in a proteomic approach of the
mammalian NPC (Cronshaw et al., 2002). ALADIN is anchored within the NPC by the trans-
membrane NUP NDC1 (Kind et al., 2009; Yamazumi et al., 2009). Together with NUP93 and
NUP214 it belongs to the group of barely exchangeable NUPs based on their dissociation rates
and residence times at the NPC and therefore seems to build the structural scaffold backbone of
the complex. ALADIN does not seem to be important for integrity of NPCs because nuclei lack-
ing the protein do not show structural impairments in these complexes (Cronshaw and Matunis,
2003). Rabut et al. classified several tryptophan-aspartic acid (WD) repeats-containing NUPs
in the group of proteins which form the stable NPC backbone. Their WD repeats can initiate
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a number of protein-protein interactions (Rabut et al., 2004). ALADIN belongs to this group
(Tullio-Pelet et al., 2000).
Most of the known AAAS mutations result in mislocalisation of the altered ALADIN protein
mainly to the cytoplasm (Cronshaw and Matunis, 2003; Krumbholz et al., 2006; Koehler et al.,
2008). It is suspected that ALADIN facilitates cell type-specific nucleo-cytoplasmic transport
and is therefore of great importance for the maintenance of distinct tissues involved in the
pathogenesis in triple A syndrome (Cronshaw and Matunis, 2003).
1.3 Oxidative stress
1.3.1 Introduction and role of the adrenal
Cellular reactive oxygen species (ROS) originate from molecular oxygen and comprise the
following molecules which all have different reaction properties: superoxide anion radical O•−2 ,
hydrogen peroxide H2O2 and hydroxyl radical HO•. Biotransformation reactions involving oxi-
dations, reductions, hydrolyses (all phase I) and conjugation reactions (phase II) are the most
common causes of ROS production. In the following I will focus on phase I reactions and
conjugation reaction involving glutathione.
An imbalance in cellular ROS levels can have deleterious effects on the cell in several ways.
DNA can be damaged by hydrogen radicals attacking purines (8-guanine), bases and sugars
can be oxidised, single-stranded and double-stranded DNA breaks can occur and proteins can
be cross-linked. Amino acids like cysteine and methionine are very likely to be affected by
ROS. In addition, free amino acid side chains can be oxidised, and proteins can be cross-
linked and fragmented. Unsaturated and saturated fatty acids involved in lipid metabolism and
sterols can easily be attacked by hydrogen radicals forming lipid peroxide radicals which have
similar effects as ROS. Moreover ROS can (dis-)regulate genes resulting in apoptosis, stress,
tumour development, fibrosis and chemokine production. Besides ROS there also exist reactive
nitrogen species which are generated of decomposed nitrogen dioxide by photons. Molecular
oxygen can also be used as photo-initiator resulting in the production of ozone. These types of
radicals will attack other cellular compartments in more aggressive ways (Dekant, 2009).
Adrenocortical cells have a huge number of mitochondria which are responsible for steroid
production and oxidative respiration. The increased turnover of lipids and uncoupling of the
respiratory chain leads to an increased risk of ROS leakage. In addition, several other bio-
reaction systems can lead to leakage of ROS when being dysregulated; among these are
xanthine/xanthine oxidase, nitric oxide synthases, NADPH-dependent oxidases and most
strikingly the adrenal cortex CYP P450s (Prasad et al., 2014b).
All CYP P450s are hemoproteins with an iron-protoporphyrin IX prosthetic group whereby
the iron undergoes cyclic oxidation Fe3+ and reduction Fe2+. Iron has six binding sites of which
five are occupied. The sixth can bind to an α-OH of the hemoprotein or water. The reaction
consists of amixed-function oxidase system in which the CYPP450 exploits the key position and
different flavoproteins interact with the reducing agent NAD(P )H (Dekant, 2009). Flavopro-
teins contain a prosthetic group flavin adenine dinucleotide (FAD) and/or flavin mononucleotide
(FMN ) and are electron transfer-proteins facilitating the redox reaction of all CYP P450s with
NAD(P )H and molecular oxygen. Type I CYP P450s rely on the flavoenzyme ferredoxin re-
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ductase (FDXR1) and type II on the microsomal flavoprotein cytochrome P450 oxidoreductase
(POR) (andNADH-CY Pb5 reductase (CY Pb5)). FDXR1 accepts two electrons fromNADPH
by FAD and transfers them firstly to ferrodoxin before passing them on to mitochondrial CYP
P450 (Pandey and Fluck, 2013; Prasad et al., 2014b). POR receives two electrons from
NADPH by FAD, passes them onto FMN and finally transfers them directly or via CY Pb5
to several microsomal CYP P450s (exemplified for CYP17A1 in Figure 6). CY Pb5 can act in
a similar fashion like POR (Pandey and Fluck, 2013). The role of POR will be described in
detail in subsection 1.5 Involvement of the endoplasmic reticulum in steroidogenesis. During
the CYP P450 redox reaction the substrate SH first binds to Fe3+-CYP P450. NAD(P )H gives
off two electrons which are passed on to CYP P450 by the previously mentioned flavoenzymes.
Oxygen is incorporated into Fe2+-CYP P450 and activated to superoxide anion. The substrate
is hydroxylated to SOH, water and Fe3+-CYP P450 are split off. The reaction steps can be
summarised in the following equation:
SH +O2 +NAD(P )H +H
+→ SOH +H2O +NAD(P )+.
Figure 6 – Electron flow to CYP17A1 is facilitated by cytochrome P450 oxidoreductase.
Cytochrome P450 oxidoreductase (POR) is an integral endoplasmic reticulum protein and binds NADPH. Two electrons are
received by flavin adenine dinucleotide (FAD) inducing a conformational change. FAD and flavin mononucleotide (FMN ) are
moved closer and the electrons are passed to FMN and further to the catalytic prosthetic heme group of CYP17A1 (P450c17)
(Pandey and Fluck, 2013).
Mitochondrial steroidogenesis significantly adds to ROS formation in the cell because un-
coupling of the CYP P450 redox reaction can occur in different steps of the reaction: during
the incorporation of molecular oxygen and during its activation. Under these circumstances
superoxide anions and hydrogen peroxide can leak and escape from the reaction (Dekant,
2009). During the last step of cortisol synthesis, the production of cortisol from 11-deoxycortisol
by CYP11B1, approximately 40 % of total electron flow is passed into ROS formation (Rapoport
et al., 1995). During the reaction of cholesterol to pregnenolone by CYP11A1 approximately
15 % of electrons are transferred into ROS formation (Rapoport et al., 1995).
1.3.2 Anti-oxidant defence in the adrenal
In contrast to other organs with a high metabolic rate like brain and liver, the adrenal gland
has a high level of enzymatic and non-enzymatic anti-oxidants. Imbalances in ROS production
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result in cellular oxidative stress and have been implicated in several different diseases including
cancer, neurological manifestations and diabetes mellitus. Therefore, an equilibrated level of
anti-oxidative mechanisms is of high importance, especially in the adrenal cortex.
Among the non-enzymatic anti-oxidants are ascorbic acid (vitamin C), α-tocopherol (vitamin
E) and coenzyme Q10.
Enzymatic anti-oxidants are superoxide dismutase (SOD), catalase and glutathione per-
oxidase (GPX). Superoxide anion radicals are detoxified by SOD to hydrogen peroxide and
molecular oxygen. Hydrogen peroxide is further inactivated to water by peroxisomal cata-
lase. Cytosolic GPX (predominantly GPX1), with the help of glutathione (GSH), and peroxi-
redoxin (predominantly PRDX3), which depends on the electron donor thioredoxin 2 (TXN2),
are also able to neutralise hydrogen peroxide. Both latter systems depend on the reducing agent
NADPH which is synthesised by nicotinamide nucleotide transhydrogenase (NNT). Regene-
rated NADPH is used to produce GSH from its oxidised form GSSG by glutathione reductase
(GSR) and by the TXN2 system to produce reduced PRDX. GPX belong to the group of seleno-
proteins and use a selenocysteine residue as redox reactive prosthetic group. The selenium
content of the adrenal is actually shown to be high (Prasad et al., 2014b). During inactivation of
hydrogen peroxide a PRDX dimer is oxidised to a disulphide dimer and reduced again by TXN2.
GPX catalyses the reaction more efficiently than the thioredoxin system (Figure 7) (Prasad et
al., 2014b).
Figure 7 – Detoxification pathways after leakage of electrons of the mitochondrial respiratory chain.
Superoxide anions O•−2 can be protonated by manganese-dependent superoxide dismutase (MnSOD) to form hydrogen peroxide
H2O2 which is in turn neutralised to result water by thioredoxin 2 (TXN2) and glutathione (GSH) systems. This antioxidants are
dependent on high levels of NADPH provided by nicotinamide nucleotide transhydrogenase (NNT) (Prasad et al., 2014b).
1.3.3 Nucleoporins and mitochondrial energy metabolism
It is suspected that a dysfunction of ALADIN may play a role in cellular accumulation of ROS
causing species-specific impairments in cells which are hypersensitive to oxidative stress. There
is increasing evidence that ALADIN-deficient cells are more susceptible to oxidative stress (Kind
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et al., 2010; Prasad et al., 2013; Jühlen et al., 2015). In fibroblast cell cultures of different triple A
syndrome patients all mean enzyme expression levels of the ROS detoxifying enzymes SOD1,
SOD2, catalase and GSR were altered. The expression of SOD1 increased significantly, the
expression of catalase decreased 0.7 fold. Furthermore it was shown that the mitochondrial
network in patient cells is more pronounced than in control fibroblasts. The maximal ATP
synthesis was the same in patient cells as in controls, but synthesis was decreased per mito-
chondrion. In addition, the rate of cell division was decreased in patient cells. It was concluded
that fibroblasts of triple A patients have a higher basal ROS level and an increased response to
artificially induced oxidative stress (Figure 8) (Kind et al., 2010).
In addition, studying differential gene expression in ALADIN-deficient or -mutated cells under
oxidative stress, it was previously seen that cells of triple A patients show an altered induction
or down-regulation of genes associated with oxidative stress and anti-oxidant defence (Koehler
et al., 2013).
Figure 8 – Model of the suspected pathogenesis in triple A syndrome.
ALADIN-deficient cells are more sensitive to oxidative stress due to several mechanisms in the cell leading to stress-induced pre-
mature senescence (SIPS). It is hypothesised that there is an ALADIN-dependent cross-talk between the nucleus and mitochondria
and mRNA export (Kind et al., 2010).
Ferritin heavy chain protein (FTH1) was identified as an interaction partner of ALADIN in a
bacterial two-hybrid screen of cDNA libraries (Storr et al., 2009). In addition to its well-known
iron storage role, FTH1 has been shown to protect the nucleus from oxidative damage. It was
hypothesised that mutant ALADIN impairs the nuclear import of FTH1 in triple A syndrome. A
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deficiency of nuclear FTH1 results in an enhanced susceptibility of cells to ROS and cellular
damage (Storr et al., 2009). Furthermore it was shown that cells of triple A patients have a
higher degree of chromosomal fragility (Reshmi-Skarja et al., 2003). Concomitantly, Hirano et
al. observed a reduced nuclear import of DNA ligase 1 (LIG1) and aprataxin (APTX) in a patient
fibroblast cell line which both have functions in DNA single strand break repair. It was concluded
that these cells have an increased sensitivity to oxidative stress (Hirano et al., 2006).
So far one other NPC component, the cytoplasmic filament RANBP2/NUP358, has been
identified to localise to the mitochondria via nuclear-encoded cytochrome oxidase assembly
protein 11 (COX11) and hexokinase type I in vitro and in vivo and to exploit a distinct mechanism
in glucose metabolism and energy homeostasis selectively in the central nervous system in
mice (Aslanukov et al., 2006; Cho et al., 2007). In humans heterozygous mutations in RANBP2
cause a neurological disorder called acute necrotising encephalopathy (MIM #608033) (Neilson
et al., 2009).
Another pathology affecting the central nervous system was found due to mutations in
the central channel nucleoporin NUP62 (autosomal recessive infantile bilateral striatal necro-
sis (IBSN) (MIM #271930)) (Basel-Vanagaite et al., 2006). Many clinical features of IBSN
overlap with Leigh syndrome (subacute infantile necrotising encephalopathy) (MIM #256000)
which is caused by mutations in nuclear- and mitochondrial-encoded genes regulating energy
metabolism (Finsterer, 2008).
The detailed pathogeneses in the described nucleoporinopathies caused by RANBP2 and
NUP62 are unclear, but it has been shown that adaptor proteins like RANBP2mediate the trans-
port of a broad range of different cargoes and aremediators of mitochondrial function and energy
maintenance (Cho et al., 2007; Neilson et al., 2009). Up to now functions of ALADIN in animal
and human cell physiology remain in parts elusive. Animal and human disease states share
some of their pathophysiological pathways leading specifically to neurological manifestations.
The increased sensitivity to oxidative stressmay be onemajor reason for the neurodegeneration
causing the various symptoms in triple A syndrome (Kind et al., 2010).
1.4 Adrenocortical disorders and redox imbalances
As discussed earlier the adrenal cortex has a great capacity of buffering ROS which are es-
pecially produced during lipid metabolism and steroidogenesis in the mitochondria. Impair-
ment in mitochondrial redox homeostasis by liberating ROS can therefore lead to uncoupling
of steroidogenic pathways. Several disorders causing adrenocortical deficiency have been
recently associated with an adrenal redox imbalance. These disorders will be summarised
in the following.
1.4.1 Familial glucocorticoid deficiency
Familial glucocorticoid deficiency (FGD) is a rare life-threatening autosomal recessive disorder
characterised by glucocorticoid deficiency and ACTH unresponsiveness. Forty-five percent of
the cases are caused by impaired ACTH signalling due to mutations in key components of
the signalling cascade: mutations in MC2R (MIM #202200) account to 25 % of FGD patients
and mutations in the adrenal specific melanocortin receptor accessory protein (MRAP) (MIM
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#607398) for further 20 % of all cases (Weber and Clark, 1994; Metherell et al., 2005; Clark et
al., 2009; Metherell et al., 2009).
The role of MRAP is trafficking of the MC2R from the ER to the surface of the cell (Webb and
Clark, 2010). Most mutations inMRAP cause retention of the MC2R at the ER, some mutations
cause reduced signalling of the receptor. These patients show a milder phenotype with later
onset than those with loss-of function in MRAP (Hughes et al., 2010).
Notably, more than 40 mutations in steroidogenic acute regulatory protein (StAR) have been
identified to cause lipoid congenital adrenal hyperplasia (LCAH) (MIM #201701), and some of
these patients were shown to develop the phenotype of a severe form of FGD (Metherell et
al., 2009; Miller and Bose, 2011). StAR initiates the first step in steroidogenesis by importing
cholesterol across the mitochondrial membrane. Most mutations in StAR causing LCAH are
loss-of function mutations. These results in excessive accumulation of cholesterol and destruc-
tion of adrenocortical cells, characteristics seen in the phenotype of LCAH (Meimaridou et al.,
2013).
In about FGD patients without mutations in MC2R and MRAP, two new genes causing
FGD have been identified. Recently, mutations in minichromosome maintenance complex
component 4 (MCM4) (MIM #609981) in an Irish Traveller community are shown to cause FGD
(O’Riordan et al., 2008; Hughes et al., 2012; Gineau et al., 2012). In addition, mutations in NNT
(MIM #614736) lead to FGD (Meimaridou et al., 2012). Novoselova et al. also described a NNT
pseudogene activation as the cause for FGD (Novoselova et al., 2014).
MCM4 codes for a DNA replicase leading to increased genomic instability, DNA break-
age during DNA replication in mitosis and natural killer cell deficiency when being mutated
(O’Riordan et al., 2008; Hughes et al., 2012; Gineau et al., 2012). NNT is a highly conserved
gene encoding an integral proton pump of the inner mitochondrial membrane catalysing the
conversion of NADP+ to NADPH by using NADH produced in the citric acid cycle (CAC)
(Meimaridou et al., 2012). Detoxification of mitochondrial ROS by GPX and PRDX3 depends
on the regeneration of NADPH (Prasad et al., 2014b). Importantly, another member of the
TXN2 system, thioredoxin reductase 2 (TXNRD2) (Figure 7), has lately been associated with
FGD (Prasad et al., 2014a).
The exact mechanisms why mutations in these genes affect the hormone production in the
adrenal cortex is not known. Both proteins, NNT and MCM4, seem to have specific functions in
adrenal cells causing the FGD phenotype (Meimaridou et al., 2013). NNT shows high protein
expression levels in the adrenal gland affecting sensitive organelles in these cells – the mi-
tochondria (Meimaridou et al., 2012). Increased ROS levels will lead to cell damage including
increased DNA strand breakage and genomic instability which resembles pathogenic features of
patients carrying MCM4 mutations. It seems that not only mitochondria, but also cell divisions
are sensitive processes in adrenocortical cells leading to impaired steroidogenesis; a clinical
hallmark in triple A syndrome patients (Hirano et al., 2006).
1.4.2 X-linked adrenoleukodystrophy
X-linked adrenoleukodystrophy (ALD) (MIM #300100)mainly affectingmales (females aremostly
symptomatic carriers) is caused by mutations in ABCD1 coding for the peroxisomal ATP -
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binding cassette, subfamily D, member 1 protein. ALD and triple A syndrome have in common
that both the nervous system and the adrenal gland are involved. The clinical manifestations in
ALD presented at any age can vary even within families. Symptoms are heterogeneous, mainly
affecting the adrenal cortex, the myelin of the central nervous system and the Leydig cells
of the testes. Adrenal insufficiency may precede neurological symptoms and can also occur
solely (Prasad et al., 2014b; Moser et al., 2000; Moser et al., 2005). Moser et al. described the
existence of seven different phenotypes affected with ALD (Moser et al., 2000).
ABCD1 is involved in peroxisomal β-oxidation of fatty acids in peripheral tissues. Muta-
tions lead to accumulation of saturated very long chain fatty acids (VLCFA) (24-30 carbons)
in plasma and body tissues due to an ineffective import into the peroxisome for degradation.
Lipid metabolism is a prerequisite for functional steroid production. Accumulation of VLCFA is
mainly seen in zonae fasciculata and reticularis of the adrenal cortex, myelin sheath and testes;
according to the affected areas of the disease (Forss-Petter et al., 1997). Therefore, the disease
is classified as a lipid-storage disease. VLCFA may interfere with adrenal steroidogenesis and
myelin production in the central nervous system. It is thought that adrenal impairment is caused
by excessive VLCFA, which (a) cannot be used for re-synthesis and steroid production, (b)
disturb balances in fatty acid precursors for cholesterol esters and that (c) can impair MC2R
signalling (Moser, 1997).
Interestingly, an involvement of oxidative stress has been seen in histology of specimens
from ALD patients and from the mouse model involving altered enzyme activities for hemoxy-
genase 1 and manganese-dependent SOD and lipid peroxidation (Powers et al., 2005). In
addition depletion of glutathione and increased levels of ROS have been determined in patient
skin fibroblasts (Fourcade et al., 2008). Decreased levels of NADPH and ATP have been
seen in ABCD1 knock-out mice suggesting an impaired energy balance (Galino et al., 2011). It
is still unclear how accumulation of VLCFA leads to the induction of oxidative stress, but there
have been proposed several hypotheses. Peroxisomes are in near communication with mito-
chondria and are additionally important for lipid metabolism in the cell; therefore disturbances
in peroxisomes would ultimately lead to mitochondrial redox imbalances (Ivashchenko et al.,
2011). In the mouse model accumulation of VLCFA is seen in mitochondria, probably directly
affecting the function of the organelle (Forss-Petter et al., 1997).
However, ABCD1 knock-out mice do not develop a phenotype as seen in ALD patients
before 16-20 weeks when locomotion alterations occur. Importantly, no ALD adrenal phenotype
could be determined in mice so far – neither under basal condition nor under stress induction
(Forss-Petter et al., 1997). This observation is consistent with the AAAS knock-out mice where
no adrenal phenotype could be analysed (Huebner et al., 2006). Presumably, both proteins
ABCD1 and ALADIN undertake a species-specific role in adrenal steroidogenesis leading to
adrenal insufficiency in both diseases.
1.5 Involvement of the endoplasmic reticulum in steroidogenesis
As already outlined, triple A patients suffer from high levels of oxidative stress and impaired
anti-oxidant defence (Kind et al., 2010; Prasad et al., 2013; Jühlen et al., 2015). Mitochondria
of these patients show impaired function and are altered in their energy homeostasis (Kind et
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al., 2010). In this subsection it will be discussed how mitochondria interact with the ER and how
this interaction can be of importance in understanding the pathogeneses of triple A syndrome.
1.5.1 Mitochondrial tethering
The translocase of the outer membrane (TOM) complex is the main entry site for all mitochon-
drial proteins which are nuclear-encoded (~99 %). It is composed of distinct subunits: the core
complex consisting of a protein-conducting channel TOM40, the central receptor TOM22 and
three smaller proteins TOM5-7. Two further receptors, TOM70 and TOM20, are associated with
the core complex (general import pore complex) (Wiedemann et al., 2009).
Mitochondrial precursor proteins contain specific target signals which guide them to differ-
ent compartments of the mitochondria. There are at least five different mitochondrial sorting
pathways described which are conducted each by different sorting and assembly machineries
within the mitochondria (Figure 9) (Wiedemann et al., 2009; Chacinska et al., 2009; Schmidt
et al., 2010; Becker et al., 2012). Subunits of the respiratory chain mediating cellular oxidative
homeostasis are both mitochondrial-encoded (the three core subunits COX1-3) and nuclear-
encoded (the remaining subunits). Nuclear-encoded proteins, like COX5, are translated on
cytosolic ribosomes and are transported into the mitochondria through TOM (Mick et al., 2011).
The identification of unidentified nuclear-encoded regulators for the assembly of the respiratory
complex and its stability shall shed light on this specific pathway. As already mentioned earlier,
COX11 co-localises with RANBP2/NUP358 in vitro and in vivo (Aslanukov et al., 2006; Cho et
al., 2007).
Figure 9 – Biogenesis of mitochondrial proteins (A) and protein sorting through the import machinery
translocase of the outer membrane (B).
The translocase of the outer membrane (TOM) complex mediates the main entry for all nuclear-encoded proteins and shuttles
them to their final mitochondrial destination by five different pathways outlined in (B). SAM, sorting and assembly machinery. MIA,
mitochondrial intermembrane space assembly machinery. TIM22, translocase of the inner mitochondrial membrane 22. TIM23,
translocase of the inner mitochondrial membrane 23. OXA, oxidase assembly machinery (Chacinska et al., 2009).
It is known that the TOM complex interacts through TOM7 with the junctions between ER
and mitochondria which are formed by the mitochondrial distribution and morphology (MDM)
complex. The MDM complex consists of maintenance of mitochondrial morphology 1 (Mmm1),
cytosolic Mdm12 and Mdm34 and Mdm10 of the outer mitochondrial membrane (Figure 10)
(Schmidt et al., 2010; Becker et al., 2012). Mmm1 is embedded in the ER membrane and
shown to be glycosylated (Kornmann et al., 2009). The MDM complex connects the outer ER
membrane with parts of the outer mitochondrial membrane and is therefore termed the ER-
mitochondrion encounter structure (ERMES).
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Figure 10 – Endoplasmic reticulum-mitochondrion junction.
The ER-mitochondrion encounter structure (ERMES) is formed by the mitochondrial distribution and morphology (MDM) complex
consisting of maintenance of mitochondrial morphology 1 (Mmm1), Mdm12, Mdm34 and Mdm10. The translocase of the outer
membrane (TOM) complex interacts through TOM7 with the junctions between ER and mitochondria. ERMES associates with the
sorting and assemble machinery (SAM) which is responsible for shuttling of β-barrel proteins of the outer mitochondrial membrane
(Schmidt et al., 2010).
These structures are thought to shuttle the transport of different molecules between the two
organelles such as lipids and calcium ions. It is highlighted that mitochondrial morphological
alterations result from defect ER-mitochondrial junctions, but the detailed molecular function of
the MDM complex is yet unknown (Schmidt et al., 2010). Recently, in yeast it has been shown
that ERMES is responsible for transfer of phosphatidylserines between the two organelles.
Phosphatidylserines are necessary for the synthesis of phosphatidylethanolamine which is an
important compound of cellular membranes and necessary for lipid metabolism (Lahiri et al.,
2014). Two dynamin-like GTPases mitofusin 1 and 2 have been shown to be essential for ER-
mitochondrion junctions and in addition, for mitochondrial steroidogenesis as shown by Duarte
and co-workers (de Brito and Scorrano, 2008; Duarte et al., 2014; Duarte et al., 2012).
1.5.2 Cytochrome P450 oxidoreductase
POR is a flavoprotein residing at the cytoplasmic site of the ER and acting as a co-factor
facilitating the redox reaction between all microsomal CYP P450 enzymes and the reducing
agent NADPH (Figure 6) (Arlt et al., 2004; Fluck et al., 2007). POR is involved in a variety
of biochemical pathways within the steroid and drug metabolism, iron homeostasis or sterol
synthesis. The flavoprotein supplies electrons to heme oxygenases, fatty acid desaturases
and elongases, squalene monooxygenase, CY Pb5 and sterol reductases (Figure 11) (Pandey
and Fluck, 2013; Fluck et al., 2007; Fluck and Pandey, 2011; Riddick et al., 2013). CY Pb5 has
been reported to be an allosteric co-factor for some interactions between POR and CYP P450s.
Since all microsomal P450s depend on POR for their catalytic reaction, the specific biochemical
steroid output can be altered even if the involved CYP P450 enzyme activity is otherwise normal
(Fluck and Pandey, 2011).
Initially, patients with POR mutations were diagnosed with Antley-Bixler syndrome. A rare
variant of congenital adrenal hyperplasia showing combined CYP17A1 and CYP21A2 deficien-
cies has been reported since 1985 and has been shown to be the cause of mutant POR in 2004
(Arlt et al., 2004; Peterson et al., 1985; Fluck et al., 2004; Miller et al., 2004). POR deficiency
(PORD) has then be separately called disordered steroidogenesis due to cytochrome P450
oxidoreductase deficiency (MIM #613571) and Antley-Bixler syndrome with genital anomalies
and disordered steroidogenesis (MIM #201750).
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Figure 11 – Role of cytochrome P450 oxidoreductase in several biochemical pathways.
Cytochrome P450 oxidoreductase (POR) regulates steroid and drug metabolism through several CYP P450 enzymes (CYP17A1,
CYP1A2, etc.). Cytochrome b5 (CY Pb5) is an allosteric co-factor donating a second electron through POR to some CYP P450s.
Many small molecules can be directly de- or inactivated by POR. Furthermore, POR donates electrons to heme oxygenases (HO)
in iron metabolism and squalene monooxygenase for sterol synthesis (Pandey and Fluck, 2013).
Since then, many different mutations in POR have been described and associated with
disturbed steroidogenesis. Many of the described mutations can be found in co-factor-binding
sites and there seems to exist specific founder mutations in distinct populations (Fluck et al.,
2007; Miller et al., 2011; Pandey and Sproll, 2014). Many patients with skeletal deformations,
ambiguous genitalia and impaired steroidogenesis have been linked to PORD. It was shown
that PORD affects steroidogenesis in adrenal and gonads; thus leading to impaired sexual
development and genital ambiguity at birth in males and females (Pandey and Sproll, 2014;
Huang et al., 2005; Pandey et al., 2004). POR knock-out is embryonic lethal in mice whereas
the liver-specific knock-out leads to decreased cellular metabolism and lipid accumulation (Shen
et al., 2002; Gu et al., 2003).
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1.6 Aims of the Study
Overall, the scaffold NUP ALADIN stabilising the structural backbone of the NPC seems to facili-
tate a cell-type specific nucleo-cytoplasmic transport and to cause a cell-type specific damage in
its absence. There exists a wide spectrum of diseases sharing clinical and cellular pathologies
with triple A syndrome. It has to be assumed that impaired function of ALADIN predominantly
affects specialised cells; neurotransmitter-releasing cells of the central and peripheral nervous
system (e.g. neurons) and secretory cells of the adrenal cortex. Regulation of adrenocortical
steroidogenesis is complex and there is increasing evidence that oxidative stress due to ROS
accumulation and mitochondria are significantly involved. Furthermore, there may be an impor-
tant cross-talk between functional organelles comprising nucleus, ER and mitochondria which
presumably involves lipid metabolism.
It is hypothesised that oxidative stress in triple A syndrome patient fibroblasts leads to
degeneration and to stress-induced premature senescence (Kind et al., 2010). Therefore, it
can be assumed that patient adrenocortical cells are likewise affected by increased levels of
oxidative stress resulting in impaired steroidogenesis and degeneration of these cells. To eluci-
date these assumptions, the cellular role of ALADIN was investigated in this study by creating
two experimental models using the adrenocortical tumour cell line NCI-H295R1, a sub-strain
showing characteristics of the glucocorticoid-producing zona fasciculata of the adrenal cortex
(Wang et al., 2012). Cells were engineered to either over-express or down-regulate AAAS
by inducible stable transfection. Subsequently, alterations in steroidogenic gene expression
were determined and functional consequences were assessed by steroid quantification from
cell supernatants employing a liquid chromatography/tandem mass spectrometry (LC/MS-MS)
method for simultaneous quantification of 13 key steroids of the adrenal steroidogenic pathway.
In addition, the role of ALADIN on cell viability, oxidative stress response and nuclear import of
APTX, LIG1 and FTH1 was examined in these models.
In an approach to identify new interaction partners of ALADIN co-immunoprecipitation (co-
IP) followed by proteome analyses using mass spectrometry was conducted in an exogenous
ALADIN over-expression model using NCI-H295R. These results were verified in endogenous
co-IP using NCI-H295R wild-type cells. The goal of this work was to elucidate the function
of ALADIN for adrenocortical steroidogenesis and its consequences for the cellular oxidative
stress response.
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2 Materials
Table 1 – Antibodies.
PRODUCT COMPANY
ALADIN antibody (B-11): sc-374073 Santa Cruz Biotechnology, Inc., Heidelberg, Germany
Alexa fluor 488 goat anti-rabbit IgG Molecular Probes, Life Technologies, Darmstadt, Germany
Alexa fluor 555 goat anti-mouse IgG Molecular Probes, Life Technologies, Darmstadt, Germany
Anti-PGRMC2 Sigma-Aldrich, Munich, Germany
Cytochrome P450 reductase antibody (ab13513) Abcam plc, Cambridge, UK
Goat anti-mouse IgG conjugated to horseradish peroxidase Invitrogen, Life Technologies, Darmstadt, Germany
Goat anti-rabbit IgG conjugated to horseradish peroxidase Cell Signalling Technology Europe B.V., Leiden, Netherlands
Monoclonal ß-actin antibody produced in mouse, clone
AC-74
Sigma-Aldrich, Munich, Germany
Normal mouse IgG and normal rabbit IgG Invitrogen, Life Technologies, Darmstadt, Germany
Table 2 – Buffer solutions and reagents.
PRODUCT COMPANY
Agarose for DNA electrophoresis SERVA Electrophoresis GmbH, Heidelberg, Germany
Amersham enhanced chemiluminescence (ECL) prime
western blotting detection system
GE Healthcare GmbH, Little Chalfont, United Kingdom
Ampicillin AppliChem GmbH, Darmstadt, Germany
Antibiotic-antimycotic solution PAA, GE Healthcare GmbH, Little Chalfont, United Kingdom
Blasticidin S InvivoGen, Toulouse, France
Bovine serum albumin Sigma-Aldrich, Munich, Germany
Carestream Kodak autoradiography GPX replenisher/fixer Kodak, Laborversand A. Hartenstein, Würzburg, Germany
COmplete protease and PhosSTOP phosphatase inhibitor
cocktail tablets
Roche Diagnostics Corporation, Indianapolis, IN, United
States
Difco LB agar and broth, Miller BD Biosciences, Heidelberg, Germany
DMEM/F12 medium Lonza, Cologne, Germany
DNA annealing solution Invitrogen, Life Technologies, Darmstadt, Germany
Doxycyline hydrochloride MP Biomedicals, Eschwege, Germany
Formaldehyde SAV LP, Flinsbach, Germany
GelRed DNA stain Biotium, Inc., Hayward, CA, United States
Glycerol Carl Roth GmbH & Co KG, Karlsruhe, Germany
Hi-Di formamide Applied Biosystems, Life Technologies, Darmstadt, Germany
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PRODUCT COMPANY
Insulin-tranferrin-selenium (ITS-G) Gibco, Life Technologies, Darmstadt, Germany
L-glutamine Lonza, Cologne, Germany
Methyl tertiary butyl ether Sigma-Aldrich, Munich, Germany
Methyl viologen dichloride (paraquat) Sigma-Aldrich, Munich, Germany
Milk powder Sigma-Aldrich, Munich, Germany
Nu-Serum BD Biosciences, Heidelberg, Germany
Paraformaledhyde Sigma-Aldrich, Munich, Germany
Phosphate buffered saline Sigma-Aldrich, Munich, Germany
Trypsin Invitrogen, Life Technologies, Darmstadt, Germany
VECTASHIELD mounting medium for fluorescence with and
without DAPI
Vector Laboratories, Burlingame, CA, USA
X-tremeGENE HP DNA transfection reagent Roche Diagnostics, Mannheim, Germany
Zeocin InvivoGen, Toulouse, France
Table 3 – Cells and enzymes.
PRODUCT COMPANY
Antarctic phosphatase New England Biolabs, Inc., Ipswich, MA, United States
Benzonase nuclease Novagen, Merck Millipore, Darmstadt, Germany
Mix & Go competent cells – strain Zymo 5α Zymo Research, Irvine, CA, United States
NCI-H295R ATCC, Manassas, United States
NCI-H295R GFP-AAAS and NCI-H295R GFP Katrin Köhler
NCI-H295R1-TR Enzo Lalli
NCI-H295R1-TR AAAS knock-down Ramona Jühlen
NCI-H295R1-TR AAAS over-expression Ramona Jühlen
NCI-H295R1-TR pcDNA4/TO empty Ramona Jühlen
NCI-H295R1-TR scrambled shRNA Ramona Jühlen
Platinum Pfx DNA polymerase Invitrogen, Life Technologies, Darmstadt, Germany
Restriction enzymes (BglII, HindIII, XhoI and PvuI) New England Biolabs, Inc., Ipswich, MA, United States
T4 ligase Invitrogen, Life Technologies, Darmstadt, Germany
T4 polynucleotide kinase New England Biolabs, Inc., Ipswich, MA, United States
18
2 MATERIALS
Table 4 – Equipment.
PRODUCT COMPANY
20 G cannula BD Biosciences, Heidelberg, Germany
24-well culture dish Corning Costar, Kaiserslautern, Germany
30 G cannula B. Braun Melsungen AG, Melsungen, Germany
3x1 inch microscope slides Engelbrecht, Edermünde, Germany
6-well culture dish Corning Costar, Kaiserslautern, Germany
70 µm ultra clear pressure sensitive sealing film Axygen Scientific, Corning Costar, Kaiserslautern, Germany
96-well culture dish Corning Costar, Kaiserslautern, Germany
96-well garbage plate Qiagen GmbH, Hilden, Germany
96-well microplate Corning Costar, Kaiserslautern, Germany
96-well PCR plate Axygen Scientific, Corning Costar, Kaiserslautern, Germany
96-well silicone rubber septa mat Corning Costar, Kaiserslautern, Germany
ABI 7300 fast real-time PCR system Applied Biosystems, Life Technologies, Darmstadt, Germany
ABI prism genetic analyzer 3130xl Applied Biosystems, Life Technologies, Darmstadt, Germany
AcroPrep 96-well filter plate Pall GmbH, Dreieich, Germany
Amersham hybond-enhanced chemiluminescence (ECL)
nitrocellulose membrane (0.45 µm)
GE Healthcare GmbH, Little Chalfont, United Kingdom
Avanti J-30I ultra centrifuge with a JA-10 and a JA-30.50 Ti
rotor
Beckman Coulter GmbH, Krefeld, Germany
Axiovert 200 M with Axiocam MRm Carl Zeiss, Jena, Germany
BBD6220 Incubator Heraeus Holding GmbH, Hanau, Germany
Biofuge prime R Heraeus Holding GmbH, Hanau, Germany
Biofuge primo R Heraeus Holding GmbH, Hanau, Germany
Borosilicate glass tube Fisherbrand, Schwerte, Germany
CASY TT- cell counter and analyzer system OLS OMNI Life Science GmbH & Co KG, Bremen, Germany
Centrifuge 5417C Eppendorf AG, Hamburg, Germany
Fresco 17 centrifuge Thermo Scientific, Fischer Scientific, Schwerte, Germany
GFP-Trap_A agarose beads ChromoTek GmbH, Planegg-Martinsried, Germany
Glass cover slip Carl Zeiss, Jena, Germany
IDL TRM 50 rolling platform IDL GmbH & Co KG, Nidderau, Germany
Illustra Sephadex G-50 DNA grade, fine GE Healthcare GmbH, Little Chalfont, United Kingdom
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PRODUCT COMPANY
Incubator Type B12 Heraeus Holding GmbH, Hanau, Germany
Infinite 200 PRO multimode microplate reader Tecan Group AG, Männedorf, Switzerland
Innova 4430 incubator shaker New Brunswick, Eppendorf, Enfield, CT, United States
Laser scanning spectral confocal microscope TCS SP2 Leica Microsystems, Mannheim, Germany
Mithras LB940 luminometer Berthold Technologies, Bad Wildbad, Germany
Multifuge 3 S-R Heraeus Holding GmbH, Hanau, Germany
MultiScreen centrifuge alignment frame Pall GmbH, Dreieich, Germany
MultiScreen column loader and scraper Merck Millipore, Merck Chemicals GmbH, Schwalbach,
Germany
Nanodrop spectrophotometer (ND-1000) NanoDrop Technologies, Wilmington, DE, USA
Nitrogen evaporator Gebrüder Liebisch Labortechnik GmbH, Bielefeld, Germany
Novex sharp pre-stained protein standard Invitrogen, Life Technologies, Darmstadt, Germany
OV3 rotation chamber Biometra GmbH, Göttingen, Germany
Petri dish Greiner Bio-One GmbH, Frickenhausen, Germany
Protein G ultraLink resin sepharose beads Pierce, Thermo Scientific, Fischer Scientific, Schwerte,
Germany
PYREX 6x8 mm cloning cylinder Sigma-Aldrich, Munich, Germany
Thermomixer comfort Eppendorf AG, Hamburg, Germany
WT16 rocking platform Biometra GmbH, Göttingen, Germany
Table 5 – Kits and assays.
PRODUCT COMPANY
Amplex red hydrogen peroxide/peroxidase assay Invitrogen, Life Technologies, Darmstadt, Germany
BigDye terminator v1.1 and v3.1 cycle sequencing Applied Biosystems, Life Technologies, Darmstadt, Germany
CellTiter-Blue cell viability assay Promega, Mannheim, Germany
DC protein assay BioRad Laboratories, München, Germany
EasyPrep pro plasmid miniprep Biozym Scientific GmbH, Hessisch Oldendorf, Germany
GoScript reverse transcription system Promega, Mannheim, Germany
GoTaq probe qPCR master mix Promega, Mannheim, Germany
GoTaq qPCR master mix Promega, Mannheim, Germany
GSH/GSSG-Glo assay Promega, Mannheim, Germany
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PRODUCT COMPANY
NucleoSpin RNA Macherey-Nagel, Düren, Germany
NUPAGE bis-Tris mini gel 4-12 %, LDS sample buffer and
reducing agent
Invitrogen, Life Technologies, Darmstadt, Germany
PureLink HiPure plasmid filter maxiprep Invitrogen, Life Technologies, Darmstadt, Germany
Table 6 – Vectors and plasmids.
CONSTRUCT PRODUCER
pcDNA4/TO Invitrogen, Life Technologies, Darmstadt, Germany
pcDNA4/TO-AAAS cDNA Ramona Jühlen
pCRII TOPO-AAAS cDNA Barbara Kind
pTER Enzo Lalli
pTER-AAAS1 and pTER-AAAS2 shRNA Ramona Jühlen
pYFP C1-LIG1, APTX -N3 and FTH1-N3 Barbara Kind
Table 7 – siRNA oligonucleotides for cloning.
SIRNA TARGET SEQUENCE
AAAS (region 1)
siRNA-forward
siRNA-reverse
GATCCATGAAATTGCAAACTCAGATTCAAGAGATCTGAGTTTGCAATTTCATTTTTTTGGAAA
AGCTTTTCCAAAAAAATGAAATTGCAAACTCAGATCTCTTGAATCTGAGTTTGCAATTTCATG
AAAS (region 2)
siRNA-forward
siRNA-reverse
GATCCGATCTGATCGCTGAATTTGTTCAAGAGACAAATTCAGCGATCAGATCTTTTTTGGAAA
AGCTTTTCCAAAAAAGATCTGATCGCTGAATTTGTCTCTTGAACAAATTCAGCGATCAGATCG
Scrambled
siRNA-forward
siRNA-reverse
GATCCAGTACTGCTTACGATACGGTTCAAGAGACCGTATCGTAAGCAGTACTTTTTTGGAAA
AGCTTTTCCAAAAAAGTACTGCTTACGATACGGTCTCTTGAACCGTATCGTAAGCAGTACTG
Oligonucleotides were ordered from Metabion international AG, Planegg/Steinkirchen, Germany.
Table 8 – PCR primer oligonucleotides.
PRIMER NAME SEQUENCE
AAAS-specific HindIII-forward cgccaagcttgccaccATGTGCTCTCTGGGGTTGTTCC
AAAS-specific XhoI-reverse cgccctcgagTTAGAGGTGGGAATGTGGGGAG
These oligonucleotides and in the following tables were ordered from Eurofins Genomics, Ebersberg, Germany.
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Table 9 – Sequencing primer oligonucleotides.
PRIMER NAME SEQUENCE
AAAS-forward exon 11 (AAAS-Ex11-1104-F) GCCGACTGCTGTTCACTGTA
AAAS-forward exon 16 (TA-WD-Exon 16/2-F) ATGACCTGCCCCTCTTTACT
AAAS-forward exon 2 (TA-WD-cd239-F) GATCCCCTAAAGACCCCTGG
AAAS-forward exon 6 (AAAS-Ex6-558-F) GGCACCCCCACACCAACAAG
AAAS-reverse exon 2 (AAAS-Ex2-280-R) GGTGATGGATGAAGGCAGTT
BGH-reverse TAGAAGGCACAGTCGAGG
BK-PCMV-IE-forward TGGGAGGTCTATATAAGCAGAGC
BK-SequFluo-forward 2 AGGACGACGGCAACTACAAGACC
BK-SequFluo-reverse CAGGATGTTGCCGTCCTCCTTGA
BK-SequFluo-reverse 2 GTACAGCTCGTCCATGCCGAGA
JG 387-forward GGATCACTCTCGGCATGG
JG 387-reverse CCTCTACAAATGTGGTATGG
Table 10 – Real-time qPCR primer oligonucleotides.
GENE LENGTH NAME SEQUENCE
AAAS
(V1: NM_015665.5)
71 bp 281AAAS-Ex7-F
282AAAS-Ex8-R
283AAAS-hSonde
CCCTACCTCCTTGTCTACCCG
CAGGTGTATGCCCAGGGTG
TCTTCTGGCTGTGCCCAAGTGCTGTC
ACTB
(V1: NM_001101.3)
189 bp hs-ß-Actin-F
hs-ß-Actin-R
hs-ß-Actin-Sonde
GCACCCAGCACAATGAAGATC
CGCAACTAAGTCATAGTCCGC
TGCTCCTCCTGAGCGCAAGTACTCC
CYP11A1
(V1: NM_0007812.2;
V2: NM_0001099773.1)
92 bp hCYP11A1-F
hCYP11A1-R
hCYP11A1-Sonde
CGGGCTCCGGAAATTACTC
CTGGCGCTCCCCAAAAAT
TTCCGCTTTGCCTTTGAGTCCATCACT
CYP11B1
(V1: NM_000497.3;
V2: NM_001026213.1)
81 bp h-CYP11B1-F
h-CYP11B1-R
TGAGGACCTGCACCTGGAAG
ATGCCTGCTCCTCCCAARTC
CYP17A1
(V1: NM_000102.3)
97 bp hCYP17A-F
hCYP17A-R
hCYP17A-Sonde
TGCTTATTAAGAAGGGCAAGGACTT
GAGTCAGCGAAGGCGATACC
TAGAGTTGCCATTTGAGGCCGCCC
CYP21A2
(V1: NM_000500.7;
V2: NM_001128590.3)
74 bp hCYP21A-Ex6F
hCYP21A-Ex7R
hCYP21A-Ex6/7-Sonde
CATAGAGAAGAGGGATCACATCGT
TCCACTGGCCTGCCACG
CTCTCCTTGTGCTGCCTCAGCTGCAT
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GENE LENGTH NAME SEQUENCE
DHCR24
(V1: NM_014762.3)
69 bp DHCR24-F
DHCR24-R
DHCR24-Sonde
CTGGCTGATGGCAGCTTTGT
CCAGGGTACGGCATAGAACAG
CGATGCACTCCGTCCGAAAACTCAGA
GAPDH
(V1: NM_002046.4;
V2: NM_001256799.1)
75 bp GAPDH-F
GAPDH-R
GCACCGTCAAGGCTGAGAAC
AGGGATCTCGCTCCTGGAA
GSR
(V1: NM_000637.3;
V2: NM_001195102.1;
V3: NM_001195103.1;
V4: NM_001195104.1)
71 bp GSR-F
GSR-R
GSR-Sonde
TATGCCCTCCACCCCTCAT
TGAAAAAATCCATCGCTGGTT
CAGATCCCCGGTGCCAGCTTAGGA
POR
(V1: NM_000941.2)
92 bp hPOR-F
hPOR-R
hPOR-Sonde
TTTGTGGAAAAGATGAAGAAAACG
GACAGGCGGTTGGCAAACT
AACATCATCGTGTTCTACGGCTCCCAGA
STAR
(V1: NM_000349.2)
98 bp hSTAR-F
hSTAR-R
hSTAR-Sonde
CAGACTTCGGGAACATGCCT
CTTAGAGGGACTTCCAGCCAA
ACCGTGCTCCGCCCTGATGACA
Table 11 – Software.
PRODUCT COMPANY
3130xl v3.0 data collection Applied Biosystems, Life Technologies, Darmstadt, Germany
7300 sequence detection v1.3.1 Applied Biosystems, Life Technologies, Darmstadt, Germany
Contig express vector NTI advance v10.3.0 Invitrogen, Life Technologies, Darmstadt, Germany
Fuji v1.48b (Fuji Is Just ImageJ) Open-source-software
Magellan - data analysis v6.6 Tecan Group AG, Männedorf, Switzerland
MASCOT v.2.2 Matrix Science, London, United Kingdom
MikroWin 2000 v4.29 Berthold Technologies, Bad Wildbad, Germany
NanoDrop spectrophotometer ND-1000 v3.5.2 NanoDrop Technologies, Wilmington, DE, USA
OLIGO primer analysis v7.60 Molecular Biology Insights Inc., CO, United States
Primer express 3.0 Applied Biosystems, Life Technologies, Darmstadt, Germany
R i386 v2.15.0 and R Studio v0.98.1074 The R Foundation for Statistical Computing, Vienna, Austria
Web-based siRNA Target Finder Matrix Science, London, United Kingdom
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3 Methods
3.1 Plasmids and vector construction for shRNA silencing of gene expression
and cDNA over-expression
For generation of the AAAS short hairpin (sh)RNA- and hAAAS cDNA-inducible NCI-H295R1
cell clones, the tetracycline-inducible T-REx system was employed. In this system the expres-
sion of a gene of interest runs under a tetracycline-inducible promoter (Figure 12). Cells were co-
transfected with the repressor-expressing plasmid pcDNA6TR and the expression plasmid with
the tetracycline response element. The inducible expression vector pTER for shRNA silencing
was generously provided by Enzo Lalli and contained a H1 promoter specific for expression
of small nuclear RNAs (van de Wetering et al., 2003). The inducible pcDNA4/TO expression
vector was used for full-length hAAAS cDNA over-expression.
Figure 12 – Tetracycline-inducible T-REx cell-expression system.
The expression of the gene of interest (eitherAAAS shRNA in pTER or cDNA in pcDNA4/TO) was under the control of a tetracycline-
inducible promoter. Cells were co-transfected with pcDNA6TR expressing a repressor tetR which binds to the operator sequence
TetO2 on the expression plasmids pTER or pcDNA4/TO and repressed expression. Upon addition of doxycycline (a tetracycline
analogue) the repressor is conformationally changed, falls off and the expression is de-repressed (Invitrogen, 2011, modified).
Double-stranded small interfering (si)RNA oligonucleotides were used as shRNA templates
(Figure 13) and were designed using the Ambion web-based algorithm siRNA Target Finder
(Invitrogen, 2015) and compared to the human genome database for no more than 16-17
contiguous base pairs of homology to other coding sequences using BLAST (U.S. National
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Library of Medicine, 2015) in order to avoid incomplete complementary with other off-target
genes. Six regions were selected to be the target sequence for shRNA silencing of AAAS (V1:
NM_015665.5) and the two best regions (1: nt279-299 AAATGAAATTGCAAACTCAGA and
2: nt410-430 AAGATCTGATCGCTGAATTTG) were used for further experiments. As a negative
control a region for a non-targeting scrambled shRNA (AAAGTACTGCTTACGATACGG) was
used. These control experiments should give rise to all non-specific effects in mammalian cells
during the stable transfection used and the shRNA silencing methodology.
To create inducible pTER expression plasmids two complementary siRNA oligonucleotides
were annealed and 5’-phosphorylated by T4 polynucleotide kinase. The oligonucleotides were
T4-ligated into BglII- and HindIII- by antarctic phosphatase 5’-dephosphorylated restriction sites
of pTER. Dephosphorylation of the vector after restriction enzyme digest decreased the effect
of self-religation of the vector itself and increased the yield of the desired generated plasmid. All
siRNA template oligonucleotides contained a 5’-BamHI overhang (5’-GATC-3’) which is com-
patible with the 3’-BglII overhang (3’-CTAG-5’) of the digested pTER (Figure 13). Reaction
mixtures are summarised in Tables 12-16.
Figure 13 –Annealed complementary double-stranded small interferingRNA template and hairpin struc-
ture of the expressed short hairpin RNA.
Here as an example AAAS region 1 small interfering (si)RNA is shown. A short loop is introduced into the siRNA sequence. After
ligation into the expression vector pTER the cell after stable transfection will express a short hairpin (sh)RNA which will be further
processed into siRNA by the enzyme Dicer and other protein complexes (Bernstein et al., 2001). This system guarantees a more
efficient shRNA gene silencing than transient siRNA transfection by target mRNA bypass mechanisms or degradation (Hairpin
structure taken from Invitrogen, 2011).
For generation of inducible pcDNA4/TO expression plasmids the full-length hAAAS cDNA
was used. The cDNA was previously cloned into the pCRII TOPO vector and the plasmid
pCRII TOPO-hAAAS cDNA (200 ng/µl) was kindly provided by Barbara Kind. Restriction sites
were introduced into the cDNA by PCR with AAAS-specific HindIII-forward and XhoI-reverse
primers using the diluted plasmid pCRII TOPO-hAAAS cDNA (1:104) as template. PCR was
conducted using Platinum Pfx DNA polymerase with proofreading and 3’ to 5’ exonuclease
activity (Table 17). Primer sequences contained specific restriction sites in order to ligate the
cDNA in the same sites in the vector after digestion of both (Table 8). The amplified hAAAS
cDNA and the pcDNA4/TO expression vector were both digested using HindIII and XhoI. The
full length cDNA was then T4-ligated between HindIII- and XhoI-sites into 5’-dephosphorylated
pcDNA4/TO. The empty vector without PCR insert was used here as negative control in order
to monitor all non-specific cellular effects after stable transfection.
All restriction digests were loaded on 1 % agarose gels in order to verify efficient DNA
restriction enzyme digest. For gel casting 3 g of agarose for DNA electrophoresis was mixed
with 300 ml Tris-borate-EDTA buffer and heated up in the microwave at 700 W for 5 minutes.
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The mixture was cooled down under stirring and 15 µl of GelRed DNA stain was added. Gels
were cast with 20 µl pockets. DNA digests were mixed 6:1 with a loading dye (30 % glycerol,
0.25 % bromophenol blue and 0.25 % xylene cyanol) and loaded beside GeneRuler 100 bp and
1 kb DNA Ladder on the gel. Agarose gels were run at 200 V for at least 45 minutes.
Table 12 – Annealing of siRNA template oligonucleotides.
COMPONENT VOLUME/REACTION [µl]
Sense siRNA (1µg/µl) 2
Antisense siRNA (1µg/µl) 2
1X DNA annealing solution 46
The annealing reaction was incubated at 90 °C for 3 minutes and at 37 °C for 60 minutes.
Table 13 – Phosphorylation of siRNA 5’-hydroxyl termini using T4 polynucleotide kinase.
COMPONENT VOLUME/REACTION [µl]
Annealed siRNA template oligonucleotides 39
5X T4 DNA ligase buffer 10
T4 polynucleotide kinase (10 U/µl) 1
Phosphorylation was done at 37 °C for 30 minutes followed by heat inactivation of the kinase at 65 °C for 20 minutes.
Table 14 – Restriction cross digest of siRNA expression vector pTER.
COMPONENT VOLUME/REACTION
Vector (2µg/µl) 10 µg
Aqua dest. Ad 100 µl
10X NEB2 buffer 10 µl
HindIII (20 U/µl)
and afterwards
BglII (10 U/µl)
5 µl
10 µl
Restriction digest with HindIII and afterwards with BglII was done at 37 °C over-night and heat inactivation of HindIII at 65 °C for
20 minutes.
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Table 15 – Dephosphorylation of pTER 5’-phosphate groups using antarctic phosphatase.
COMPONENT VOLUME/REACTION
Digested pTER vector 10 µg
10X Antarctic phosphatase reaction buffer 10 µl
Antarctic phosphatase (5 U/µl) 2 µl
Dephosphorylation was done at 37 °C for 15 minutes and heat inactivation of the phosphatase at 65 °C for 20 minutes.
Table 16 – Ligation of siRNA inserts and pTER vector using T4 ligase.
COMPONENT 1:5 RATIO 1:10 RATIO VECTOR CONTROL INSERT CONTROL
Aqua dest. Ad 20 µl Ad 20 µl Ad 20 µl Ad 20 µl
5X T4 ligase buffer 4 µl 4 µl 4 µl 4 µl
Vector 4494 bp (0.1 µg/µl) 50 ng 50 ng 50 ng -
Insert 63 bp (7 ng/µl) 3.5 ng 7 ng - 3.5 ng
T4 ligase 1 1 1 1
Vector and inserts were ligated at 14 °C over-night. Calculation of vector and insert DNA at a ratio of free molecule ends of 1:1:
ng insert = bp insert∗50 ng vector
bp vector
Table 17 – Amplification of hAAAS cDNA using Platinum Pfx DNA polymerase.
COMPONENT VOLUME/REACTION [µl]
10X Pfx amplification buffer 5
dNTP mixture (10 mM) 1.5
MgSO4 (50 mM) 1
Primer mix (10 µM each) 1.5
Template DNA
pcRII TOPO-hAAAS cDNA
(1 : 104)
1
Platinum Pfx DNA polymerase 0.4
Ultra pure water Ad 50
The DNA template was denatured in an initialisation step at 94 °C for 2 minutes. Amplification was done using three-step cycling:
firstly denaturation of the DNA template at 94 °C for 15 seconds, secondly annealing of the primers at 60 °C for 30 seconds and
thirdly DNA extension at 68 °C for 1 minute per kb. The PCR was repeated for 35 cycles. Final hold was at 10 °C.
Investigation of nuclear import processes was done using C- or N-terminal fluorescent pro-
tein vectors (pFP C1 or pFP N3). Full length cDNA of LIG1 (V1: NM_000234.2), APTX (V1:
NM_175073.2; V6: NM_001195248.1; V7: NM_001195249.1) and FTH1 (V1: NM_002032.2)
were cloned to create pYFP C1-LIG1, APTX -N3 pYFP and FTH1-N3 pYFP plasmids. These
plasmids were kindly provided by Barbara Kind.
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All ligation products and provided plasmids were transformed into Mix & Go competent
cells – strain Zymo 5α using the manufacturer’s protocol. Ampicillin (100 µg/µl) as selection
reagent for all plasmids was used in Difco LB agar and broth at a concentration of 100 µg/ml.
Transformed bacteria (either 10 or 60 µl per plate) were split out on 20 ml Difco LB agar, Miller,
petri dishes and grown over-night at 37 °C in an incubator Type B 12. Bacteria were picked
using 10 µl pipette tips and seeded in 3 ml Difco LB broth, Miller, at 37 °C and 230 rpm over-
night using an Innova 4430 incubator-shaker. Bacterial DNA was isolated using EasyPrep
pro plasmid miniprep kit as described in the manufacturer’s protocol. For maxi preparations
500 µl of subsequent mini preparation bacterial culture were initially mixed with 50 ml Difco
LB broth, Miller, and incubated for at least 4 hours at 37 °C and 230 rpm. The subsequent
culture was then mixed with 200 ml Difco LB broth, Miller, and incubated over-night at 37 °C
and 230 rpm. Bacterial DNA was isolated using PureLink HiPure plasmid filter maxiprep kit
as described in the protocol of the manufacturer using an Avanti J-30I ultra centrifuge with a
JA-10 (17700x g) and JA-30.50 Ti (108800x g) rotor. Glycerol stocks were prepared of each
bacterial maxi prep culture expressing the plasmid of interest (500 µl maxi prep culture mixed
with 500 µl 50 % glycerol). All plasmid constructs were confirmed by DNA sequencing to rule
out introduced bacterial mutations. An overview of all generated plasmid constructs can be
found in section 2 Materials.
3.2 DNA sequencing
DNA sequencing reactions were done using BigDye terminator v1.1 and v3.1 cycle sequencing
kit, the ABI Prism genetic analyzer 3130xl and 3130xl v3.0 data collection Software. Following
sequencing reactions AcroPrep 96-well filter plates were filled with 45 µl illustra Sephadex G-
50 DNA grade, fine, using the MultiScreen column loader and scraper. To each well 300 µl
deionised water was added. The mixture was incubated at least 3 hours at 4 °C covered with the
lid and centrifuged at 1613x g for 3minutes on amultifuge 3 S-R using theMultiScreen centrifuge
alignment frame and a corresponding 96-well plate. The water was discarded and subsequently,
20 µl of cycle sequencing reactions were pipetted onto the Sephadex columns to get rid off
cycle sequencing reaction components. AcroPrep 96-well filter plates were centrifuged again as
described and cleaned sequencing products were caught in round-bottom 96-well microplates.
Hi-Di formamide (10 µl) was pipetted into 96-well PCR plates and 2 µl of the clean sequencing
product was added. Plates were sealed with 96-well silicone rubber septa mats, spinned down
and proceeded to sequencing analysis.
Plasmid constructs using the inducible siRNA expression vector pTER were verified by se-
quencing using the vector-intern BGH-reverse primer and constructs obtained by the inducible
pcDNA4/TO expression vector were verified using the vector-intern BGH-reverse primer and
whole AAAS cDNA-spanning primers: AAAS-forward primer for exon 2 (TA-WD-cd239-F) and
reverse primer for exon 2 (AAAS-Ex2-280-R), forward primer for exon 6 (AAAS-Ex6-558-F),
exon 11 (AAAS-Ex11-1104-F) and exon 16 (TA-WD-Exon 16/2-F) and HindIII-forward primer.
For sequencing of plasmids used for the investigation of nuclear import processes (pFP C1
or pFP N3) the following primers were used: the cloned cDNA in the pYP C1 construct (LIG1)
was verified using JG 387-forward and -reverse primers and in the pYP N3 constructs (APTX
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and FTH) using BK-PCMV-IE-forward and BK-SequFluo-reverse primers. For sequencing the
fluorescent protein (YFP) of the fusion proteins in both plasmid constructs BK-SequFluo-forward
2 and -reverse 2 primers were used. All sequencing primers were generated using OLIGO
Primer Analysis Software v7.60 and sequences were analysed using Contig Express Vector
NTI Advance v10.3.0.
3.3 Cell culture and treatments
NCI-H295R1-TR cells containing a tetracycline response system, expressing a repressor bin-
ding to the tetracycline response element, were kindly provided by Enzo Lalli (Doghman et al.,
2007; Nogueira et al., 2009). The cells were cultured in DMEM/F12 medium supplemented
with 1 mM L-glutamine, 5 % Nu-serum, 1 % insulin-transferrin-selenium (ITS-G), 1 % antibiotic-
antimycotic solution (100 U penicillin/ml, 0,1 mg/ml streptomycin sulphate and 0.25 µg/ml am-
photericin B) and 5 µg/ml blasticidin S. The vector pcDNA6TR expressing the repressor, binding
to the tetracycline response element on the expression plasmids, contained a blasticidin S
resistance gene. Cells expressing the vector of choice will grow in the presence of 5 µg/ml
blasticidin S. Cells were maintained in a 37 °C humidified atmosphere (5 % CO2) using a
BBD6220 Incubator.
For generation of NCI-H295R1-TR stably expressing AAAS shRNA (NCI-H295R1-TR AAAS
knock-down) the cells were transfected with the two different pTER-AAAS1 and pTER-AAAS2
shRNA vectors or the pTER-scrambled shRNA vector as a control cell line (NCI-H295R1-TR
scrambled shRNA).
For generation of NCI-H295R1-TR stably expressing hAAAS cDNA (NCI-H295R1-TR AAAS
over-expression), the pcDNA4/TO-AAAS cDNA was transfected into NCI-H295R1-TR. NCI-
H295R1-TR cells stably expressing empty pcDNA4/TO were generated in addition without PCR
product insert as a control cell line (NCI-H295R1-TR pcDNA4/TO empty).
NCI-H295R1-TR cells with AAAS knock-down shRNA, scrambled shRNA, AAAS over -
expression and pcDNA4/TO empty vector were selected and cultured with 100 µg/ml zeocin
in culture media. Doxycyline hydrochloride (a tetracycline analogue) was used at 1 µg/ml for
48 hours to turn on the expression of the subsequent integrated gene or shRNA sequences.
The most reliable sub-clones were selected and one clone per construct type was chosen
(AAAS knock-down shRNA, scrambled shRNA, AAAS over-expression and pcDNA4/TO empty
vector). Selected NCI-H295R1-TR cell lines were cultured in 6-well culture dishes at a density
of 2x105 cells/well and treated 24 hours after seeding with doxycyline for 48 hours. In order to
determine efficiency of AAAS knock-down, over-expression and expression of genes coding for
steroidogenic enzymes total RNA was isolated from one well and used for real-time RT-PCR.
In addition, whole protein was isolated from two wells and ALADIN expression was verified on
protein level. Steroid production was determined by LC/MS-MS of the cell media of three wells.
Experiments were repeated six times.
For analysis of oxidative stress response NCI-H295R1-TR AAAS knock-down, scrambled
shRNA,AAAS over-expression and pcDNA4/TO empty cells were stimulated with 0.2mMmethyl
viologen dichloride (paraquat) for 24 hours.
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NCI-H295R cells stably expressing GFP-ALADIN fusion protein or GFPwere kindly provided
by Katrin Köhler. In order to generate these cells the γ-retroviral transfervectors pcz-CFG5.1-
GFP-AAAS and pcz-CFG5.1-GFP were co-transfected with the packaging plasmids pHIT60 (a
plasmid expressing murine leukaemia virus group-specific antigen and polymerase-integrase-
replicase) which enable viral encapsulation and DNA integration and replication, respectively)
and pMD.G (a plasmid expressing vesicular stomatitis virus protein G which facilitates viral entry
into the host cell) into the packing cell line HEK 293T in order to produce pseudo retroviruses
(Kind et al., 2009; Temme et al., 2003). NCI-H295Rwild-type cells were transduced with pseudo
retroviruses containing pcz-CFG5.1-GFP-AAAS and pcz-CFG5.1-GFP.
NCI-H295R wild-type cells and NCI-H295R cells stably expressing GFP-ALADIN fusion
protein or GFP were cultured in DMEM/F12 medium supplemented with 1 mM L-glutamine,
5 % Nu-serum, 1 % ITS-G and 1 % antibiotic-antimycotic solution. Cells were maintained in a
37 °C humidified atmosphere (5 % CO2).
3.4 Stable and transient adrenal cell transfection
NCI-H295R1-TR cells were cultured in 6-well culture dishes containing medium supplemented
with 5 µg/ml blasticidin S at a density of 1.6x105 cells/well 24 hours before subsequent trans-
fections. Cells were counted with CASY TT - cell counter and analyzer system. Cells were
transfected using X-tremeGENE HP DNA transfection reagent following the manufacturer’s
protocol. All plasmids were used at a concentration of 0.01 µg/µl diluted in pure DMEM/F12
at an optimised transfection ratio of 2:5. DNA-transfection reagent mixtures were left at room-
temperature for 15 minutes and were given in drop wise manner to the cells. For stable trans-
fections, pTER and pcDNA4/TO plasmid constructs (10 µg) were linearised prior transfections
by digestion with PvuI (20 U). At 50 % confluency after transfection cells were split 1:4 and
sub-cultured in 6-well culture dishes containing medium supplemented with 100 µg/ml zeocin.
Zeocin resistance was contained on pTER and on pcDNA4/TO and subsequently the resistance
was expressed in those cells carrying the plasmid of interest. Clones appeared after approxi-
mately 4 weeks and were transferred each into one well of 24-well culture dishes by the use of
PYREX 6x8 mm cloning cylinders. Clones were grown up and at a confluency of 70 % split at
a ratio of 1:3.
For transient transfections of pYFP C1-LIG1, APTX -N3 and FTH1-N3, 105 cells of NCI-
H295R1-TR AAAS knock-down, scrambled shRNA, AAAS over-expression and pcDNA4/TO
empty cells were sub-cultured onto glass cover slips in 6-well culture dishes. During transfection
1 µg/ml doxycycline was added to the medium. After 24 hours the medium was changed and
cells were grown for additional 24 hours in the presence of doxycycline.
3.5 RNA extraction, cDNA synthesis and quantitative real-time PCR using Taq-
Man
Total RNA was isolated directly from the well using the NucleoSpin RNA according to the pro-
tocol from the manufacturer using a Centrifuge 5417C. Purity of the RNA was assessed using
Nanodrop spectrophotometer (ND-1000) and NanoDrop spectrophotometer ND-1000 software
v3.5.2. RNA was stored at -80 °C until use. The amount of 500 ng of total RNA was reverse
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transcribed with usage of the GoScript reverse transcription system following the protocols from
the manufacturer and cDNA was stored at -20 °C.
Primers and probes for the quantitative amplification of the target sequence using TaqMan
were designed using Primer Express 3.0 and compared to the human genome database for
unique binding using BLAST search. The primer sequences, probes and gene accession num-
bers used for the amplification of specific target sequences are listed in section 2 Materials:
ß-actin (ACTB), AAAS, CYP11A1, CYP17A1, CYP21A2, GSR, POR and StAR. Real-time PCR
is a quantitative measurement of PCR amplification as it occurs during the exponential growth
phase (exact doubling of product at every PCR cycle). TaqMan technology is based on the
usage of two PCR primers and one probe which is labelled with a reporter dye and a quencher.
During PCR primers and probe anneal to the target and during extension the Taq polymerase
uses 5’-nuclease activity to degrade the reporter. The dye will be unquenched and emit fluores-
cence. The fluorescence is proportional to the amount of PCR product synthesised. A specific
hybridisation is prerequisite for fluorescence emission and reduces background and especially
false positive amplification products (Sherrill et al., 2004).
The qPCR amplifications were performed in triplicates using the GoTaq probe qPCR master
mix according to the manufacturer’s reaction parameters; using 20 µl total reaction volumes in
96-well PCR plates with 70 µm ultra clear pressure sensitive sealing films on an ABI 7300 fast
real-time PCR system with the 7300 sequence detection software v1.3.1. The 20X primer stock
solutions were prepared in a light insensitive tube as follows: 35.7 µl forward and reverse primer
each (stock: 100 pmol/µl), 10 µl TaqMan probe (stock: 100 pmol/µl) and 118.6 µl nuclease-free
water. As a reference dye 17 µl of carboxy-X-rhodamine was freshly added to each 1 ml tube
of master mix. As housekeeping gene for normalisation ACTB was used. Positive controls
contained a random mix of cDNA and negative controls contained nuclease-free water instead
of cDNA.
In all real-time qPCR experiments relative gene expression was calculated using the Ct
method using standard and semi-log plots of amplification curves. Subsequently, the measured
mRNA of each sample was firstly normalised to the gene expression relative of ACTB and
secondly to a calibrator. In each case the calibrator was the native doxycycline-uninduced sam-
ple. Finally, results were expressed either in gene expression relative to ACTB or in percentile
change in gene expression relative to ACTB and calibrator as follows:
% change = Ct sampleCt calibrator ∗ 100.
In all results repeatability was assessed by standard deviation of triplicate Cts and repro-
ducibility was verified by normalising all real-timeRT-PCR experiments by theCt of each positive
control per run. The guidelines of the Minimum Information for Publication of Quantitative Real-
Time PCR Experiments were followed in this work to allow more reliable interpretation of real-
time RT-PCR results (Bustin et al., 2009; Bustin, 2010; Bustin et al., 2013).
3.6 Quantitative real-time PCR using a DNA-binding dye as reporter
Total RNA was extracted and reverse transcribed from NCI-H295R1-TR AAAS knock-down,
scrambled shRNA,AAAS over-expression and pcDNA4/TO empty cells as described previously.
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Primers for the amplification of the target sequence were designed using OLIGO primer
analysis software v7.60 and compared to the human genome database for unique binding using
BLAST search. All primer sequences and gene accession numbers used for the amplification
of specific target sequences are listed in section 2 Materials: CYP11B1, 24-dehydrocholesterol
reductase (DHCR24) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). During dye-
based real-time PCR two primers were used and a double-stranded DNA-binding fluorophore.
During PCR extension the dye will be integrated in the DNA, the target amplicon will increase
and fluoresce. The fluorescence will be proportional to the amount of product but including
non-specific amplified double-stranded DNA (false positives) (Sherrill et al., 2004; Wittwer et
al., 2013).
The qPCR amplifications were performed in duplicate using the GoTaq qPCR master mix
according to the manufacturer’s reaction parameters and as described previously; using 20 µl
total volumes. The 20X primer stock solutions were prepared as follows: 40 µl forward and
reverse primer each (stock: 100 pmol/µl) and 120 µl nuclease-free water. As a reference
dye carboxy-X-rhodamine was added to the qPCR reaction mixture. As housekeeping gene
for normalisation GAPDH was used. Positive controls contained a random mix of cDNA and
negative controls contained nuclease-free water instead of cDNA.
In all real-time qPCR experiments relative gene expression was calculated using the Ct
method described previously. Results were presented in gene expression relative to GAPDH. In
all results repeatability was assessed by standard deviation of duplicate Cts and reproducibility
was verified by normalising all real-time qPCR experiments by the Ct of each positive control
per run. False positive measurements due to primer dimerisation during the amplification reac-
tion were excluded by comparing the melting peaks of the negative controls with those of the
samples. No secondary peak was observed in any of the PCR products which would indicate
a secondary non-specific PCR product.
3.7 Chromatographic-mass spectrometric conditions and sample preparation
Steroids were isolated from 1 ml of NCI-H295R1-TR AAAS knock-down, scrambled shRNA,
AAAS over-expression and pcDNA4/TO empty cell culture supernatant by liquid/liquid extraction
using 3 ml of methyl tertiary butyl ether in borosilicate glass tubes. Samples were vortexed twice
for 5 seconds at highest speed, spinned down and subsequently frozen at -20 °C for at least
an hour. The top organic layer was poured off into a new clean and dry glass tube. The frozen
aqueous layer was discarded. Samples were evaporated for 15 minutes at 55 °C and 0.5 bar
using a nitrogen evaporator.
Samples were reconstituted in 200 µL of 50/50 methanol/water. They were analysed at the
Centre for Endocrinology, Diabetes andMetabolism, School of Clinical & Experimental Medicine
(Birmingham, United Kingdom) by LC/MS-MS on a Waters Xevo Mass Spectrometer with an
Acquity ultra-Performance Liquid Chromatography system as described previously (Haring et
al., 2012). Steroids were separated using a HSS T3 1.2 x 50 mm column by LC and identified in
positive ionisation using electrospray ionisation mode by the mass analyser. The system set-up
is described in Table 18.
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Steroids were quantified by comparison to a calibration series ranging from 0.5 to 1000 ng/ml
and set off against total protein content (µg) per well, which represents the cell number. Steroid
concentrations were expressed inmMol/g total protein content and each sample was normalised
to its native doxycycline-uninduced state giving the percentile change in steroid output as fol-
lows:
% change = steroid conc. samplesteroid conc. native ∗ 100.
All steroids were quantified using a suitable internal standard listed in Table 19. A set of
steroids was considered covering the steroid bio-pathway; cortisol, cortisone, 11-deoxycortisol
(compound S), corticosterone, androstenedione, testosterone, 5α-dihydrotestosterone, dehy-
droepiandrosterone, 17-hydroxyprogesterone (17OHP), deoxycorticosterone (DOC), proges-
terone, pregnenolone and 17-hydroxypregnenolone. Two mass transitions were required to
positively quantify each steroid.
Table 18 – Liquid chromatography/mass spectrometry system parameters.
LC/MS SYSTEM SET-UP CRITERIA
Capillary voltage 0.8-1.5 kV (depending on most recent tune file)
Collision energy 8-26 eV (depending on the mass transition)
Column HSS T3, 1.8 µm, 1.2x50 mm column
Column temperature 60 °C
Cone voltage 14-30 V
Desolvation temperature 600 °C
Flow rate 0.6 ml/min
Injection volume 20 µL
Ionisation mode Positive
Seal wash 10 % methanol
Solvent A1 Water (LC/MS grade) 0.1 % formic acid
Solvent B1 Methanol (LC/MS grade) 0.1 % formic acid
Solvents A2 and B2 50/50 methanol/water
Source Electrospray source
Source temperature 150 °C
Strong wash Solvent B
System Waters Xevo mass spectrometer
uPLC Acquity uPLC system
Weak wash 50/50 methanol/water
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Table 19 – Mass transitions and retention times of steroids.
STEROID ABBREVIATION QUANTIFIER
TRANSITION
(precursor > product)
QUALIFIER
TRANSITION
(precursor > product)
11-deoxycortisol S 347 > 97 347 > 109
11-deoxycortisol-d2 S-d2 349 > 97 349 > 109
17-hydroxypregnenolone 17OHPreg 297 > 279 297 > 159
17-hydroxypregnenolone-d3 17OHPreg-d3 336 > 300 336 > 105
17-hydroxyprogesterone 17OHP 331 > 97 331 > 109
17-hydroxyprogesterone-d8 17OHP-d8 339 > 100 339 > 113
Androstenedione A’dione 287 > 97 287 > 109
Corticosterone B 347 > 121 347 > 97
Corticosterone-d8 B-d8 355 > 125 355 > 100
Cortisol F 363 > 121 363 > 97
Cortisol-d4 F-d4 367 > 121 367 > 331
Cortisone E 361 > 163 361 > 121
Dehydroepiandrosterone DHEA 289 > 253 289 > 271
Dehydroepiandrosterone-d6 DHEA-d6 277 > 219 277 > 259
Deoxycorticosterone DOC 331 > 109 331 > 97
Dihydrotestosterone DHT 291 > 255 291 > 159
Dihydrotestosterone-d3 DHT-d3 294 > 258 294 > 159
Pregnenolone Preg 317 > 299 317 > 281
Pregnenolone-d4 Preg-d4 321 > 303 321 > 285
Progesterone Prog 315 > 97 315 > 109
Progesterone-d9 Prog-d9 324 > 100 342 > 113
Testosterone Test 289 > 97 289 > 109
Testosterone-d3 Test-d3 292 > 109 292 > 97
Steroids in italic represent internal standards.
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3.8 Cell viability assay
Formeasurement of cell viability, NCI-H295R1-TRAAAS knock-down, scrambled shRNA,AAAS
over-expression and pcDNA4/TO empty cells were sub-cultured at a density of 104 cells/well
onto 96-well culture dishes. After 24 hours medium was added containing doxycycline. After
another 48 hours one part of the cells was exposed to oxidative stress with 0.2 mM paraquat
for 24 hours.
Cell viability was measured in triplicate in a final volume of 120 µl of paraquat-treated and
untreated cells using CellTiter-Blue cell viability assay according to the manufacturer’s proto-
col. Viable cells metabolised the redox dye resazurin to the red-fluorescent oxidation product
resorufin by redox reactions. Non-viable cells did not produce a fluorescent metabolic end-
product. Thus, the amount of resorufin was proportional to the amount of viable cells. Fluores-
cence emission at 590 nm of resorufin was measured after 4 hours using the Infinite 200 PRO
multimode microplate reader and the Magellan - data analysis software v6.6. The experiments
were repeated at least six times.
3.9 Measurement of total and oxidised glutathione
For measurement of GSH and its oxidised form (GSSG), NCI-H295R1-TR AAAS knock-down,
scrambled shRNA, AAAS over-expression and pcDNA4/TO empty cells were sub-cultured at
a density of 104 cells/well onto white-walled and white-bottomed 96-well culture dishes. After
24 hours the medium containing doxycyline was added. After another 48 hours cells were
exposed to oxidative stress as described above.
The substrate luciferin-NT was converted to luciferin in a GSH-dependent reaction by glu-
tathione-S-transferase. Luciferin was further used as substrate in a firefly luciferase reaction.
Light emission was dependent on the amount of luciferin and in turn of GSH in the cell. Thus,
the amount of detected light was proportional to the amount of GSH in the cell. Total GSH by
converting all glutathione in the cell to GSH and GSSG by blocking GSH were measured in
triplicate using GSH/GSSG-Glo assay and the protocol recommended by the manufacturer.
Luminescence was recorded after 15 minutes using the Mithras LB940 luminometer and the
MikroWin 2000 software v4.29. An integration time of 0.5 sec for each 96-well-micro plate was
used. The experiments were repeated at least five times.
3.10 Hydrogen peroxide assay
To detectH2O2 released from and within cells, NCI-H295R1-TR AAAS knock-down, scrambled
shRNA, AAAS over-expression and pcDNA4/TO empty cells were sub-cultured at a density of
104 cells/well onto 96-well culture dishes. After 24 hours the medium containing doxycycline
was added. After another 48 hours the cells were exposed to oxidative stress with 0.2 mM
paraquat for 24 hours.
The concentration ofH2O2 was measured in a final volume of 100 µl in triplicate of paraquat-
treated and untreated cells using Amplex red hydrogen peroxide/peroxidase assay according to
themanufacturer’s protocol. Amplex red reagent reacts withH2O2 and produces the fluorescent
oxidation product resorufin. Fluorescence emission at 590 nm of resorufin was measured after
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5 hours using the Infinite 200 PROmultimodemicroplate reader and theMagellan - data analysis
software v6.6. The experiments were repeated at least four times.
3.11 Nuclear import processes and microscopy
Transient transfected NCI-H295R1-TR AAAS knock-down, scrambled shRNA, AAAS over -
expression and pcDNA4/TO empty cells grown on glass cover slips were washed three times
with PBS, fixed with 4 % PFA in PBS for 10 minutes, followed by a three wash-step with PBS
for 5 minutes and mounted onto 3x1 inch microscope slides with VECTASHIELD mounting
medium for fluorescence without DAPI. For oxidative stress treatment cells were induced for
another 24 hours with 0.2 mM paraquat before fixation.
Fluorescence was recorded using Axiovert 200 M and pictures taken using x40 objective,
Axiocam MRm and filter set 38HE (excitation BP470/40, beam splitter FT 495, emission BP
525/50). Bright-field and fluorescence pictures were analysed using Fuji v1.48b (Fuji Is Just
ImageJ). All input pictures were grey-scaled with auto exposure time for each picture. Cell
cytosols and nuclei were analysed semi-automatically. Each cell cytosol of a series of pictures
of a transient transfected cell type was measured automatically using the auto-threshold feature
of ImageJ (Method Triangle) and the subsequent nucleus was marked manually. Region of
interests (ROIs) of cytosols and nuclei were extracted on basis of the bright-field picture. These
ROIs were transferred to the fluorescence picture and measured, giving the following data val-
ues for fluorescence intensity of cytosol and nucleus each: mean, median, minimum, maximum,
area, standard deviation, percentage distribution, ratio (meannucmeancyt ) and especially for the nuclei,
nucleus numbering (in order to verify and double-check the automatic process). Output values
for fluorescence intensity of cytosols and nuclei ranged from 0 to 255; consequently, value 0
resembles no fluorescence intensity and value 255 maximum fluorescence intensity. Ratios
were plotted in order to ascertain potential import impairment. The experiments were repeated
twice.
3.12 Immunoblots
All cells were trypsinised, pelleted for 5 minutes at 220x g using a Biofuge primo R washed
twice with PBS and centrifuged. Pellets (~10 µl) were subsequently lysed in 100 µl ice-cold
lysis buffer containing 50 mM Tris (pH 7.4), 100 mM NaCl, 4 % sodium dodecyl sulfate, 1 %
Triton X-100 and protease-phosphatase inhibitor (1 tablet/10 ml buffer, freshly prepared). Cell
lysis and shearing was done using three times each a 20 G and a 30 G cannula. In order to
avoid viscosity due to high DNA amount an additional step of 3 µl benzonase nuclease treatment
for 30 minutes at 37 °C was done using a Thermomixer Comfort. Lysates were centrifuged at
15000x g using a Biofuge prime R for 5 minutes and the pellet was discarded. Protein con-
centration was measured using the colorimetric DC protein assay according to manufacturer’s
instructions. The biochemical assay exhibits an improved version of the method first described
by Lowry (Lowry et al., 1951). Lysates were stored at -80 °C over-night.
Before loading 50 µg of protein per lane onto a NUPAGE bis-Tris mini gel samples were pre-
pared with NUPAGE lithium dodecyl sulfate (LDS) sample buffer (4X), reducing agent (10X) and
deionised water by heating the samples at 70 °C for 10 minutes using a Thermomixer Comfort.
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LDS will denature the protein backbone and disulphide protein bonds will be reduced render-
ing the samples optimal for gel electrophoresis. After LDS-polyacrylamide gel electrophoresis
(PAGE) separation (150 V for 1.5 hours) and electroblotting (30 V for 1.5 hours) onto Amersham
hybond-enhanced chemiluminescence (ECL) nitrocellulose membrane (0.45 µm) non-specific
binding of proteins to the membrane was blocked by incubation in PBS containing 3 % BSA at
room-temperature using a Biometra WT16 rocking platform. The membrane was then probed
with primary antibodies either anti-ALADIN (B-11): sc-374073 (1:100 in 3 % PBS/BSA), anti-
POR (ab13513) (1:1000 in 5 % milk powder in PBS), anti-progesterone receptor membrane
component 2 (anti-PGRMC2) (1:200 in 5 % PBS/milk powder) or anti-ACTB (clone AC-74)
(1:20000 in 3 % PBS/BSA) over-night at 4 °C. Membranes were washed with 0.1 % Tween-20 in
PBS for 30 minutes and secondary antibodies goat anti-mouse IgG conjugated to horseradish
peroxidase (1:2000 in 3 % PBS/BSA) or goat anti-rabbit IgG conjugated to horseradish perox-
idase (1:3000 in 5 % PBS/milk powder) were incubated one hour at room-temperature. Mem-
branes were washed again for 30 minutes followed by detection using an Amersham ECL
prime Western Blotting detection system using the protocol of the manufacturer. Blots were
subsequently exposed to x-ray films and antigen bands visualised by autoradiography using
Carestream Kodak autoradiography GPX replenisher/fixer.
3.13 Co-immunoprecipitation using agarose and sepharose beads
NCI-H295R wild-type cells and NCI-H295R cells stably transduced with GFP-ALADIN fusion
protein or GFP were trypsinised and pelleted as described previously. Pellets (∼ 107 cells)
were subsequently lysed with 200 µl of ice-cold lysis buffer containing 10 mM Tris (pH 7.5),
150 mM NaCl, 0.5 mM EDTA, 0.5 % NP-40 and protease-phosphatase inhibitor using a syringe
as described previously. In order to avoid viscosity due to high DNA amount an additional
step of 3 µl benzonase nuclease treatment was done, cell lysates were spinned and protein
concentration was measured as described before. Lysates were stored at -80 °C until use.
For co-IP of GFP lysates from NCI-H295R cells expressing GFP-AAAS were used. Lysates
from cells expressing GFP were used as negative control for all unspecific protein interactions
due to the exogenous expression model using a GFP fusion protein. Bead slurry (25 µl) of
GFP-Trap_A agarose beads, which are antibody fragments of alpaca against GFP bound to an
agarosematrix, was equilibrated in 500 µl ice-cold dilution buffer containing 10mMTris (pH 7.5),
150 mM NaCl, 0.5 mM EDTA and protease-phosphatase inhibitor. Beads were spinned down
at 2500x g for 2 minutes at 4 °C on a Fresco 17 centrifuge and washed twice with 500 µl
ice-cold dilution buffer. Cell lysates (500 µg protein in dilution buffer adjusted to 500 µl) of
NCI-H295R cells stably expressing GFP-ALADIN (27 + 59 kDa) or GFP (27 kDa) as control
were added to the beads and gently resuspended by flipping the tube. The GFP and GFP-
fusion proteins were bound over-night at constant mixing on a IDL TRM 50 rolling platform at
4°C. The tubes were spinned down and the supernatants were discarded. The beads were
washed twice with 500 µl ice-cold dilution buffer and transferred to a new tube before the last
wash step. The beads were gently resuspended in 60 µl NUPAGE LDS sample buffer (2X)
and in order to dissociate the captured immunocomplexes from the beads, boiled at 95 °C
for 10 minutes using a Thermomixer Comfort. The beads were collected by centrifugation at
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2500x g for 2 minutes at 4 °C and Western Blot analysis was conducted with 20 µl of the eluate
(referred to as bound fraction) as described previously. For Western Blot analysis besides
eluates whole protein lysate (input), non-bound and wash fractions were used, in order to adjust
co-IP methodology. The left 40 µl of the eluate was further processed for proteomic profiling
using mass spectrometry (Figure 14). These experiments following mass spectrometry analysis
were repeated three times.
For co-IP of ALADIN using lysates fromNCI-H295R wild-type cells Protein G UltraLink Resin
sepharose beads were used: 20 µl bead slurry was equilibrated in 500 µl ice-cold dilution buffer
and spinned down at 2500x g for 2 minutes at 4 °C as described above. Beads were gently
resuspended in ALADIN antibody (B-11): sc-374073 (2 µg/ml) and as negative control normal
mouse IgG (2 µg/ml) in 200 µl dilution buffer. With the control experiment unspecific protein
binding to IgG antibodies was ruled out. Antibody and IgGs were bound to the beads over-night
at 4 °C in a Biometra OV3 rotation chamber. Beads were spinned down and washed once to get
rid of excess antibody and IgGs. Cell lysates (500 µg protein in 500 µl dilution buffer) of NCI-
H295Rwild-type cells were added to the beads and gently resuspended by flipping the tube. The
antigens were bound over-night to the antibody-beads-complex as described before. The tubes
were spinned down and supernatants were discarded. The beads were washed four times and
transferred to a new tube before the last wash step. The beads were gently resuspended in 60 µl
sample buffer containing dilution buffer, NUPAGE LDS sample buffer (1X) and reducing agent
(1X). The captured immunocomplexes were dissociated and the eluates were collected and
processed by Western Blot analysis as described previously. The experiments were repeated
three times. For Western Blot analysis besides eluates whole protein lysate (input), non-bound
and wash fractions were used, in order to adjust co-IP methodology. In addition, the left 40 µl
of the eluate after ALADIN co-IP and negative control using IgGs were further processed for
proteomic profiling using mass spectrometry (Figure 14). These experiments following mass
spectrometry analysis were conducted once.
Figure 14 – Schematic presentation of co-immunoprecipitation followed by mass spectrometry.
After incubation of beads, equipped with a specific antibody, with cell lysate the protein of interest will bind to the antibody bound
to the matrix. Unspecific protein-binding will be eliminated by wash steps and after elution (here, for facilitation, the antibody
will not be eluted next to the immunocomplexes) the immunocomplexes will be separated using sodium/lithium dodecyl sulfate
(SDS/LDS)-polyacrylamide gel electrophoresis (PAGE) and processed to mass spectrometry. The principles described here are
the same for the co-immunoprecipitation (co-IP) method using lysates from NCI-H295R wild-type cells besides that an additional
step for antibody binding is required (Australian Proteome Analysis Facility Ltd, 2015).
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3.14 Proteomic profiling using mass spectrometry
Protein complexes of co-IPs using lysates fromNCI-H295R cells expressingGFP-AAAS, lysates
from NCI-H295R wild-type cell and controls were eluted and 40 µl of these fractions were load
on the seventh lane after the protein marker Novex Sharp prestained protein standard of a
NUPAGE bis-Tris mini gels. Gel electrophoresis was done as described previously followed
by a wash-step of the gels in aqua dest. The gels were subsequently stained for 30 minutes in
Coomassie staining solution containing 50%methanol, 7.5% acetic acid and 10mgCoomassie
brilliant blue R250. For controlled destaining an acetic acid solution containing 30 % methanol
and 7.5% acetic acid was used until the degree of preferred staining was achieved. The staining
procedure was firstly described by Meyer and Lambert proposing a negatively charged protein-
dye complex (Meyer and Lamberts, 1965). Finally, the gel was washed in aqua dest and further
processed for mass spectrometry.
Entire gel lanes were cut into 40 slabs, each of which was in-gel digested with trypsin
(Shevchenko et al., 2006). Gel analyses were performed at the Mass Spectrometry Facility
at the Max Planck Institute for Molecular Cell Biology and Genetics (Dresden, Germany) on
a nano high-performance liquid chromatograph Ultimate interfaced on-line to a LTQ Orbitrap
Velos hybrid tandem mass spectrometer (Vasilj et al., 2012). Database search was performed
against International Protein Index human database (downloaded in July 2010) and NCBI pro-
tein collection without species restriction (updated in June 2014) using MASCOT software v.2.2
under the following settings: enzyme specificity-trypsin; two miscleavages; mass tolerance 2.0
and 0.5 Da for precursor and fragments, respectively; variable modifications-deamidation of
asparagine and glutamine, oxidation of methionine, acetyl of the protein N-terminus and propi-
onamide of cysteine. Scaffold software v.4.3.2 was used to validate tandemmass spectrometer-
based protein identifications. Peptide identifications were accepted if they could be established
at greater than 95.0 % probability by the Peptide Prophet algorithm with Scaffold delta-mass
correction (Keller et al., 2002), protein identifications at greater than 99.0 % and contained at
least one (co-IP conducted with lysates fromNCI-H295Rwild-type cells) or two (co-IP conducted
with lysates from NCI-H295R cells expressing GFP-AAAS) unique identified peptides (number
of different amino acid sequences, regardless of any modification, that are associated only with
this protein). Protein probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii
et al., 2003). The assumption Scaffold used for converting search engine results into peptide
probabilities were examined manually using the MASCOT scoring function histogram. Proteins
that contained similar peptides and could not be differentiated based on MS/MS analysis alone,
were grouped to satisfy the principles of parsimony. Quantitative spectrum values were nor-
malised to the total spectra.
3.15 Immunofluorescent staining
NCI-H295R wild type cells grown on glass cover slips were washed three times with PBS, fixed
for 5 minutes with 2 % formaldehyde in PBS, permeabilised for 10 minutes with 0.5 % Triton-X-
100 in PBS and fixed again for 5 minutes. Glass cover slips were washed three times with 0.1 %
Triton-X-100 for 5 minutes and blocked for 30 minutes with 2 % PBS/BSA at room-temperature.
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Primary antibodies ALADIN (B-11): sc-374073 (1:25 in 2 % PBS/BSA) or cytochrome P450
reductase (ab13513) (1:100 in 2 % PBS/BSA) were incubated at 4 °C over-night in a humid-
ified chamber. Cells were washed again three times for 5 minutes and secondary antibodies
alexa fluor 555 goat anti-mouse IgG and alexa fluor 488 goat anti-rabbi IgG (1:500 in 2 %
PBS/BSA) were incubated one hour at room-temperature in the dark followed by a three wash-
step for 5 minutes. Glass cover slips were mounted onto microscope slides with VECTASHIELD
mounting medium for fluorescence with DAPI protected from light. Fluorescence was visualised
using the laser scanning spectral confocal microscope TCS SP2 and pictures taken using x63
oil immersion objective, helium neon laser 543 nm, argon/argon krypton-laser 488 nm and diode
405 nm. The experiment was repeated at least three times.
3.16 Statistics
Statistical analyses were made using the open-source-software R i386 v2.15.0 and R Studio
v0.98.1074. All values were expressed as a mean ± standard deviation. As assumption of
normality (goodness-of-fit) the following tests were conducted: Shapiro-Wilk-test and Q-Q-Plot.
Unpaired and paired Student’s t-tests were used. During evaluation of the results a confidence
interval α of 95 % and p values lower than 0.05 were considered as statistically significant.
Results are shown as box plots which give a fast and efficient overview about median, first
and third quartile (50th, 25th and 75th percentile, respectively), interquartile range, minimal and
maximal values and outliers. Box plots give an intuitive impression of position and statistical
spread of the measurement.
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4 Results
4.1 Generation of two different ALADIN expression models
In the first part of the results the cellular role of ALADIN was investigated by creating two
experimental models using NCI-H295R1. These cells were engineered to either over-express
or down-regulate AAAS by inducible stable transfection. Alterations in steroidogenic gene ex-
pression and functional consequences were determined. In addition, the role of ALADIN on cell
viability and oxidative stress response was analysed in these distinct models.
Down-regulation and over-expression of AAAS was confirmed on mRNA level (Figure 15 A-
B) (n=6; n gives the minimum number of independent experiments) and on protein level by
Western Blot (Figure 15 C-D) (n=6). The establishment of stable doxcycline-inducible ALADIN
knock-down and over-expression sub-clones of the adrenocortical cell line NCI-H295R1-TR
was successful.
Figure 15 – Down-regulation and over-expression of AAAS on mRNA and protein level.
Knock-down and over-expression in stably transfected NCI-H295R1-TR cells was induced by treatment with doxycycline for 48 h:
(A-B) Boxplots of down-regulation and over-expression of AAAS on mRNA level (TaqMan analysis) and (C-D) evidence of down-
regulation and over-expression of AAAS on protein level (Western Blot). Scr, scrambled shRNA. KD, knock-down. EV, empty
vector (= pcDNA4/TO). OE, over-expression. Native, without doxycycline induction. Dox, doxycycline induction. n, minimum
number of independent experiments. P-values: * P < 0.05, ** P < 0.01, *** P < 0.001. Significant differences were measured with
paired and unpaired Student’s t-Test. Boxplot widths are proportional to the square root of the samples sizes. Whiskers indicate
the range outside 1.5 times the inter-quartile range above the upper quartile and below the lower quartile. Outliers were plotted as
dots (Jühlen et al., 2015).
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Without doxycycline stimulation a partial AAAS knock-down and over-expression was ob-
served when compared to the subsequent controls (Figure 15). Many of the positive results pre-
sented in this work were based on the doxycycline untreated cells and it had to be assumed that
the T-REx system used as method of choice appeared to be leaky. The repressor-expressing
plasmid pcDNA6TR seemed to be out-numbered in each cell model by the inducible expression
vectors pTER for shRNA silencing and pcDNA4/TO for hAAAS cDNA over-expression which
both contain the tetracycline-response element. In the doxycycline-uninduced state the amount
of repressor produced seemed not to be enough in order to block expression of shRNA or
hAAAS cDNA leading to the partial AAAS knock-down and over-expression described here.
4.2 Impairment of glucocorticoid and androgenic steroidogenesis and of POR
by ALADIN deprivation
To investigate the effects of AAAS knock-down and over-expression on steroidogenesis mRNA
expression of key enzymes involved in steroidogenesis was assessed including CYP11A1,
CYP11B1, CYP17A1, CYP21A2, DHCR24, POR and StAR. In addition steroid production em-
ploying LC/MS-MS was measured in NCI-H295R1-TR AAAS knock-down and AAAS over-
expression cells. With quantitative RT-PCR it was revealed that AAAS knock-down induced
a significant down-regulation of the genes coding for enzymes involved in the glucocorticoid
and androgenic pathways, i.e. 17α-hydroxylase/17,20lyase (CYP17A1) and 21-hydroxylase
(CYP21A2) (n=6) (Figure 16 A). Expression ofStAR,CYP11A1,DHCR24 andCYP11B1was not
affected in these cells (Figures 17 A, 18 A and 18 C). Similar effects were observed in the func-
tional steroid output of the cells measured by LC/MS-MS. Changes in steroid production inAAAS
knock-down cells were predominantly observed for 17OHP, compound S and androstenedione
(n=6) (Figure 16 B), whereas only minor changes in the remaining ten steroids were observed.
Thus, for simplification, the following results focus on those three steroids. There was no change
in precursor metabolites of the mineralocorticoid pathway (DOC) (Figure 19 A). Furthermore it
was seen that the ALADIN-dependent impairment of the glucocorticoid and androgenic path-
ways is accompanied by a down-regulation of the gene coding for POR, an enzyme managing
electron transfer from NADPH to CYP17A1 and CYP21A2 microsomal P450 hydroxylases
(Figure 16 C). A decrease in POR gene expression was observed in knock-down cells prior
to doxycycline treatment, most likely representing the partial AAAS knock-down presented in
Figure 15 A and C.
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Figure 16 – TaqMan analyses (A and C) and LC/MS-MS (B) of stably transfected NCI-H295R1-TR AAAS
knock-down cells.
Cells were treated for 48 h with doxycycline. Scr, scrambled shRNA. KD, knock-down. 17OHP, 17-hydroxyprogesterone. A’dione,
androstenedione. Compound S, 11-deoxycortisol. n, minimum number of independent experiments. P-values: * P < 0.05, **
P < 0.01, *** P < 0.001. Significant differences were measured with paired and unpaired Student’s t-Test. Boxplot widths are
proportional to the square root of the samples sizes. Hundred percent boxes for native scrambled shRNA and knock-down are
not shown. Whiskers indicate the range outside 1.5 times the inter-quartile range above the upper quartile and below the lower
quartile. Outliers were plotted as dots (Jühlen et al., 2015).
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Figure 17 – TaqMan analyses of stably transfected NCI-H295R1-TR AAAS knock-down and over-
expression cells.
(A-B) StAR and CYP11A1 of AAAS knock-down and over-expression cells, (C) CYP17A1 and CYP21A2 and (D) POR of AAAS
over-expression cells. Knock-down and over-expression in stably transfected NCI-H295R1-TR cells was induced by 48 h treatment
with doxycycline. Scr, scrambled shRNA. KD, knock-down. EV, empty vector (=pcDNA4/TO). OE, over-expression. Native, without
doxycycline induction. Dox, doxycyline induction. n, number of independent experiments. Boxplot widths are proportional to the
square root of the samples sizes. Whiskers indicate the range outside 1.5 times the inter-quartile range above the upper quartile
and below the lower quartile. Outliers were plotted as dots (Jühlen et al., 2015).
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Figure 18 – Quantitative real-time PCR of stably transfected NCI-H295R1-TR AAAS knock-down and
over-expression cells.
(A-B) DHCR24 and (C-D) CYP11B1 of AAAS knock-down and over-expression cells. Knock-down and over-expression in stably
transfected NCI-H295R1-TR cells was induced by 48 h treatment with doxycycline. Scr, scrambled shRNA. KD, knock-down. EV,
empty vector (=pcDNA4/TO). OE, over-expression. Native, without doxycycline induction. Dox, doxycycline induction. n, number
of independent experiments. Boxplot widths are proportional to the square root of the samples sizes. Whiskers indicate the range
outside 1.5 times the inter-quartile range above the upper quartile and below the lower quartile. Outliers were plotted as dots
(Jühlen et al., 2015).
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Figure 19 – LC/MS-MS of stably transfected NCI-H295R1-TR AAAS knock-down and over-expression
cells.
(A) DOC of stably transfected NCI-H295R1-TR AAAS knock-down and over-expression cells and (B) 17OHP, a’dione and com-
pound S of AAAS over-expression cells. Induction with doxycycline was done for 48 h. Scr, scrambled shRNA. KD, knock-down.
EV, empty vector (=pcDNA4/TO). OE, over-expression. DOC, deoxycorticosterone. 17OHP, 17-hydroxyprogesterone. A’dione,
androstenedione. Compound S, 11-deoxycortisol. n, number of independent experiments. Boxplot widths are proportional to the
square root of the samples sizes. Whiskers indicate the range outside 1.5 times the inter-quartile range above the upper quartile
and below the lower quartile. Outliers were plotted as dots (Jühlen et al., 2015).
AAAS over-expression in at least four triplicate experiments did not result in significant dif-
ferences in expression of key enzymes involved in steroidogenesis and also did not impact on
steroid production (Figures 17 B-D, 18 B, 18 D and 19, respectively).
4.3 Alteration of cellular redox homeostasis under exogenous oxidative stress
Cell viability in both the AAAS knock-down and over-expression models was investigated. To
determine the role of ALADIN in redox homeostasis, it was ascertained how AAAS knock-down
and over-expression affect the ratio between GSH and GSSG. When cells are exposed to
increased levels of oxidative stress, NADPH decreases and GSSG accumulates. Conse-
quently, the GSH/GSSG ratio decreases which is a good indicator for cellular oxidative stress.
NADPH is used by GSR to generate the anti-oxidantGSH from its oxidised formGSSG. GSR
expression was measured in both AAAS expression models in order to verify a GSR-dependent
redox pathway disturbance leading to accumulation of GSSG.
4.3.1 Cell viability with and without exogenous oxidative stress
In NCI-H295R1-TR AAAS knock-down cells exposed to paraquat for 24 h (n=7) a significant de-
crease was observed in cell viability with oxidative stress compared to treated control cells was
observed (Figure 20 A). Viability was not decreased after doxycycline treatment in scrambled
shRNA-transfected cells. However, a decrease was seen in knock-down cells prior to doxycy-
cline treatment, most likely representing the partial AAAS knock-down presented in Figure 15 A
and C. The fully induced AAAS knock-down did not lead to a further decrease in cell viability
after paraquat exposure. Cell viability without oxidative stress was not significantly altered.
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Figure 20 – Analysis of (A-B) cell viability, (C-D) glutathione ratios and (E-F) hydrogen peroxide pro-
duction under oxidative stress.
ALADIN knock-down and over-expression in stably transfected NCI-H295R1-TR was induced by 48 h treatment with doxycycline
and cells were additionally treated with 0.2 mM paraquat for 24 h. Em, fluorescence emission at 590 nm. GSH, reduced
glutathione. GSSG, oxidised disulphide glutathione. H2O2, hydrogen peroxide. Scr, scrambled shRNA. KD, knock-down. EV,
empty vector (=pcDNA4/TO). OE, over-expression. Native, without doxycycline induction. Dox, doxycycline induction. n, minimum
number of independent experiments. P-values: * P < 0.05. Significant differences were measured with unpaired Student’s t-Test.
Boxplot widths are proportional to the square root of the samples sizes. Whiskers indicate the range outside 1.5 times the inter-
quartile range above the upper quartile and below the lower quartile. Outliers were plotted as dots (Jühlen et al., 2015).
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Surprisingly, in AAAS over-expressing cells similar effects were observed after paraquat
treatment (n=6) (Figure 20 B). Viability was not altered after doxycycline induction in the control
cells carrying the empty vector. However, cell viability was already significantly decreased
after paraquat treatment in the native over-expression cells without the induction of doxycycline
representing a partial AAAS over-expression shown in Figure 15 B and D. The fully induced
over-expression cells did not reveal further alteration in viability after treatment with paraquat.
Cell viability without oxidative stress did not result in any significant change.
4.3.2 GSH/GSSG ratio with exogenous oxidative stress
GSH/GSSG ratios were markedly decreased in NCI-H295R1-TR AAAS knock-down and over-
expression cells after paraquat treatment for 24 h compared to treated control cells (n=5) (Fig-
ure 20 C and D).
However, in cells with the partial AAAS knock-down and over-expression without induction
of doxycycline GSH/GSSG ratios were already significantly down-regulated and no further
impairment after doxycycline induction could be observed.
4.3.3 Hydrogen peroxide production with exogenous oxidative stress
In order to give further evidence that ALADIN is involved in the oxidative stress response of
the cell H2O2 production was measured in stably transfected cells after exposure to oxidative
stress. It was presumed that after oxidative stress treatment the oxidants NADPH and GSH
will decrease leading to a rise of H2O2. Cells presenting an impaired oxidative response con-
comitantly suffer from an increased ROS level and cellular damage.
Consistent with the results of cell viability analysis and GSH/GSSG ratio in NCI-H295R1-
TR AAAS knock-down cells after paraquat treatment a significantly increased level of H2O2
concentration in these cells compared to paraquat-treated control scrambled shRNA cells was
seen (n=4) (Figure 20 E). After doxycycline induction in NCI-H295R1-TR AAAS knock-down
cells no further significant increase ofH2O2 concentration could be observed; the partial knock-
down without induction of doxycycline shown in Figure 15 A and C is enough to disturb the
oxidative response of the cell. In AAAS over-expressing cells with or without doxycycline induc-
tion significant changes in H2O2 concentration could not be observed after paraquat treatment
compared to control cells carrying the empty vector (n=5) (Figure 20 F).
4.3.4 Gene expression of glutathione reductase
Analysis of the expression level of GSR showed that there was no significant change in expres-
sion level in NCI-H295R1-TR AAAS knock-down cells compared to scrambled-shRNA control
cells with or without doxycycline (n=4) (Figure 21 A).
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Figure 21 – TaqMan analyses of glutathione reductase of stably transfected NCI-H295R1-TR AAAS
knock-down and over-expression cells.
Stably transfected NCI-H295R1-TR AAAS knock-down cells and over-expression were treated for 48 h with doxycycline. GSR,
glutathione reductase. Scr, scrambled shRNA. KD, knock-down. EV, empty vector (=pcDNA4/TO). OE, over-expression. Native,
without doxycycline induction. Dox, doxycycline induction. n, minimum number of independent experiments. P-values: *** P <
0.001. Significant differences were measured with unpaired Student’s t-Test. Boxplot widths are proportional to the square root of
the samples sizes. Hundred percent boxes for native scrambled shRNA and knock-down are not shown. Whiskers indicate the
range outside 1.5 times the inter-quartile range above the upper quartile and below the lower quartile. Outliers were plotted as
dots (Jühlen et al., 2015).
In contrast GSR expression level in NCI-H295R1-TR AAAS over-expression cells without
induction of doxycycline was significantly reduced compared to control cells carrying the empty
vector used for the over-expression vector construct (n=4) (Figure 21 B). Induction with doxycy-
cline in AAAS over-expression cells increases the GSR expression level, but the increase was
not statistically significant.
Overall, the results indicate that the redox response afterAAAS knock-down in NCI-H295R1-
TR under exogenous oxidative stress using paraquat is significantly impaired and leads to accu-
mulation of hydrogen peroxide. The expression of GSR was not affected in AAAS knock-down
cells under basal conditions, implying a normal prerequisite of anti-oxidant defence at GSR
expression level when applying paraquat. AAAS over-expression cells suffer from decreased
viability and glutathione levels under oxidative stress. In these cells the expression of GSR was
reduced under basal conditions implying an increase of sensitivity during exogenous oxidative
stress.
4.4 Disturbance of nuclear import of aprataxin, DNA ligase 1 and ferritin heavy
chain 1
Using both the human adrenal NCI-H295R1-TRAAAS knock-down and over-expressionmodels
the potential impairment of the nuclear import of APTX, LIG1 and FTH1 was investigated. For
this YFP-specific vectors transiently transfected into the cell lines were employed.
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4.4.1 Nuclear import in AAAS knock-down cells
The nuclear import of APTX, LIG1 and FTH1 was markedly impaired after ALADIN deprivation
(n=26, n=83 and n=51, respectively; n gives the minimum number of analysed cells per cell
type) (Figures 22 A-C and 23). Nevertheless, nuclear import was not changed after doxycycline
treatment but already in the native state without doxycycline induction probably reflecting a
partial AAAS knock-down. The induced AAAS knock-down did not lead to a further decrease
of nuclear import of APTX, LIG1 and FTH1 compared to the native state without doxycycline
induction (Figure 22 A-C). Upon treatment with paraquat for 24 h a significant increase was
found in nuclear import of FTH1 in scrambled-shRNA control cells and AAAS knock-down cells,
but there was no significant difference between paraquat-treated scrambled-shRNA control cells
and AAAS knock-down cells (n=26) (Figure 24 A).
Figure 22 – Analyses of fluorescent microscopy of the nuclear import of aprataxin (A), DNA ligase 1 (B)
and ferritin heavy chain 1 (C-D).
ALADIN knock-down and over-expression in stably transfected NCI-H295R1-TR cells was induced by 48 h treatment with doxy-
cycline. Scr, scrambled shRNA. KD, knock-down. EV, empty vector (=pcDNA4/TO). OE, over-expression. Native, without
doxycycline induction. Dox, doxycycline induction. n, minimum number of analysed cells per cell type. P-values: * P < 0.05,
** P < 0.01, *** P < 0.001. Significant differences were measured with unpaired Student’s t-Test. Boxplot widths are proportional
to the square root of the samples sizes. Whiskers indicate the range outside 1.5 times the inter-quartile range above the upper
quartile and below the lower quartile. Outliers were plotted as dots. The experiment was repeated twice (Jühlen et al., 2015).
50
4 RESULTS
Figure 23 – Nuclear import of ferritin heavy chain 1-tagged YFP (pYFP-N3-FTH1).
Results of fluorescent microscopy of transiently transfected NCI-H295R1-TR scrambled shRNA and AAAS knock-down cells. NCI-
H295R1-TR cells were treated for 48 h with doxycycline. Scr, scrambled shRNA. KD, knock-down. Dox, doxycycline induction
(Jühlen et al., 2015).
Figure 24 – Fluorescent microscopy of the nuclear import of ferritin heavy chain 1 after treatment with
paraquat.
NCI-H295R1-TR cells were treated for 48 h with doxycycline. Scr, scrambled shRNA. KD, knock-down. EV, empty vector
(=pcDNA4/TO). OE, over-expression. Native, without paraquat treatment. PQ, paraquat treatment. n, minimum number of
analysed cells per cell type. P-values: * P < 0.05, *** P < 0.001. Significant differences were measured with unpaired Student’s
t-Test. Boxplot widths are proportional to the square root of the samples sizes. Whiskers indicate the range outside 1.5 times
the inter-quartile range above the upper quartile and below the lower quartile. Outliers were plotted as dots. The experiment was
repeated twice (Jühlen et al., 2015).
4.4.2 Nuclear import in AAAS over-expression cells
Cells over-expressing ALADIN did not show any change in nuclear import of APTX and LIG1
(n=55 and n=50, respectively) (Figure 25). Interestingly, the import of FTH1 was markedly im-
paired (n=22) (Figure 22D). The nuclear import of FTH1was already impaired in the doxycycline-
untreated AAAS over-expressing cells and no further impairment could be observed after doxy-
cycline induction. When treating control cells carrying the empty over-expression vector and
AAAS over-expression cells with 0.2 mM paraquat for 24 h FTH1 was significantly imported
into the nucleus (n=172) (Figure 24 B). There was a significant difference in FTH1 import after
paraquat treatment between control and over-expressing cells.
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Figure 25 – Analyses of fluorescent microscopy of stably transfected NCI-H295R1-TR AAAS over-
expression cells.
Nuclear import of (A) aprataxin and (B) DNA ligase 1. Induction with doxycycline was done for 48 h treatment. EV, empty vector
(=pcDNA4/TO). OE, over-expression. Native, without doxycycline induction. Dox, doxycycline induction. n, minimum number of
analysed cells per cell type. Boxplot widths are proportional to the square root of the samples sizes. Whiskers indicate the range
outside 1.5 times the inter-quartile range above the upper quartile and below the lower quartile. Outliers were plotted as dots. The
experiment was repeated twice (Jühlen et al., 2015).
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4.5 ALADIN co-immunoprecipitation in an adrenal cell model expressing exoge-
nous GFP-ALADIN and endogenous ALADIN
Co-IP was conducted in an adrenal cell model expressing exogenous GFP-ALADIN and en-
dogenous ALADIN. For GFP-ALADIN co-IP whole cell lysates of NCI-H295R cells stably over-
expressing the GFP-ALADIN fusion protein and as negative control NCI-H295R cells stably
over-expressing the GFP protein were used. Efficient co-IP using GFP-Trap agarose beads is
presented in Figure 26 A. Both over-expressed proteins, GFP-ALADIN and GFP, were success-
fully fished in the bound fractions of each specific cell lysate. No eluted GFP antibodies were
detectable on the Western Blot due to the antibody’s alpaca origin which was not recognised
by the secondary antibody used. The experiments were repeated three times.
Figure 26 – Western Blot of bound fractions after co-immunoprecipitation of GFP (A) and of ALADIN
(B).
(A) Whole cell lysates of GFP-ALADIN and GFP (as negative control) over-expressing NCI-H295R cells were prepared for GFP
co-immunoprecipitation (co-IP). Primary antibodies against GFP and ALADIN were used for Western Blot. GFP-ALADIN fusion
protein and GFP were found in each specific bound fraction implying efficient fishing of each of the proteins. No ALADIN was
detectable in the control fraction of GFP co-IP. (B) Whole cell lysates of NCI-H295R wild-type cells were prepared for ALADIN
co-IP. A mouse monoclonal antibody against ALADIN and normal mouse IgGs as negative control were used for co-IP. A primary
antibody against ALADIN was used for Western Blot. ALADIN was found in the specific bound fraction implying efficient fishing of
the protein. No ALADIN was detectable in the control fraction of normal mouse IgGs. The bound antibodies to the bead matrix
were revealed on Western Blot: heavy chains appeared at the size of 55 kDa.
For co-IP of endogenous ALADIN whole cell lysates of NCI-H295R wild-type cells were pre-
pared using Protein G UltraLink sepharose beads. A mouse monoclonal ALADIN antibody and
normal mouse IgGs as negative control were coupled each to the sepharose beads and antigen
was bound. Successful co-IP is shown in Figure 26 B. The protein was found in the bound
fraction of the ALADIN co-IP, but the negative control remained empty implying no unspecific
fishing of ALADIN. The bound and eluted antibodies to the beads were revealed on Western
53
4 RESULTS
Blot: heavy chains appeared at the size of 55 kDa (Figure 26 B). The co-IP and Western Blot
was repeated three times.
Bound fractions of GFP-ALADIN co-IP (n=3) and of co-IP of endogenous ALADIN (n=1)
were conducted for tandem mass spectrometry proteomic analyses. In GFP-ALADIN co-IP
about 500 proteins or protein precursors were identified. Proteins simultaneously found in
the negative control experiments were excluded and only those were selected which could
be reproduced in all three independent GFP-ALADIN co-IP experiments. In co-IP analysis of
endogenous ALADIN also about 500 proteins or precursors were detected and those excluded
which were found in the negative control experiment. Proteomic results and identified proteins
can be reviewed in Table 20 for GFP-ALADIN and Table 21 for endogenous ALADIN co-IP
verified by GFP-ALADIN co-IP.
Table 20 – Functional classification of proteins identified by mass spectrometry analyses after co-
immunoprecipitation of GFP-ALADIN.
PROTEIN METABOLISM GENE
CITRIC ACID CYCLE (CAC)/GLYCOLYSIS
Tricarboxylate transport protein, mitochondrial* CAC SLC25A1
Mitochondrial 2-oxoglutarate/malate carrier protein CAC SLC25A11
2-oxoglutarate dehydrogenase, mitochondrial CAC OGDH
cDNA FLJ55072, highly similar to succinate dehydrogenase
(ubiquinone) flavoprotein subunit, mitochondrial*
CAC, electron transport chain complex
II
SDHA
Malate dehydrogenase Malate/aspartate shuttle for CAC MDH1
Malate dehydrogenase, mitochondrial CAC MDH2
Isoform 1 of adipocyte plasma membrane-associated protein* Arylesterase activity, acetate synthesis APMAP
6-phosphofructokinase type C Glycolysis PFKP
6-phosphofructokinase, muscle type isoform 1* Glycolysis PFKM
Fructose-bisphosphate aldolase Glycolysis ALDOA,
ALDOB,
ALDOC
Glucose-6-phosphate isomerase Glycolysis GPI
Isoform of α-enolase* Glycolysis ENO1
LIPID METABOLISM/STEROIDOGENESIS
Isoform 1 of lysophospholipid acyltransferase 7 Phospholipid metabolism MBOAT7
Isoform 1 of trans-2,3-enoyl-CoA reductase Fatty acid synthesis and elongation TECR
Sterol O-acyltransferase 1 Cholesteryl ester formation SOAT1
Sterol-4-α-carboxylate 3-dehydrogenase, decarboxylating* Cholesterol biosynthesis NSDHL
Progesterone receptor membrane component 2* CYP P450 regulation PGRMC2
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PROTEIN PROCESSING
cDNA FLJ61290, highly similar to neutral α-glucosidase AB* Glycan metabolism, protein
N-glycolsylation
GANAB
Dolichol-phosphate mannosyltransferase Protein N-glycosylation DPM1
Dolichyl-diphosphooligosaccharide–protein glycosyltransferase
subunit 2*
Protein N-glycosylation RPN2
Malectin Protein N-glycosylation MLEC
Isoform 1 of translocon-associated protein subunit α* ER translocon complex SSR1
Elongation factor 1-gamma* Protein biosynthesis and anchorage EEF1G
Elongation factor 2 Protein biosynthesis, translation,
ribosomal translocation
EEF2
Glutaminyl-tRNA synthetase* Protein biosynthesis QARS
Lysosome-associated membrane glycoprotein 1* Presents sugars to selectins LAMP1
Lysosome membrane protein 2* Lysosomal receptor SCARB2
Protein ERGIC-53* Protein recycling and sorting,
mannose-specific
LMAN1
Perilipin-3 isoform 3* Mannose-6 receptor transport PLIN3
Isoform 1 of minor histocompatibility antigen H13 Intra-membrane proteolysis of signal
peptides from a pre-protein
HM13
Protein disulphide-isomerase A3* Protein processing PDIA3
Protein disulphide-isomerase A4 Protein processing PDIA4
Protein disulphide-isomerase* Protein processing P4HB
OTHER PATHWAYS
14-3-3 protein eta Universal signalling pathways YWHAH
14-3-3 protein gamma Universal signalling pathways YWHAG
14-3-3 protein theta Universal signalling pathways YWHAQ
14-3-3 protein zeta/delta* Universal signalling pathways YWHAZ
Isoform long of 14-3-3 protein beta/alpha Universal signalling pathways YWHAB
EF-hand domain-containing protein D2 Calcium-binding EFHD2
Galectin-7 Growth control LGALS7
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OTHER PATHWAYS
Isoform 1 of protein SET DNA-binding, inhibition of histone 4
deacetylation and DNA demethylation
SET
Isoform 2 of sarcoplasmic/endoplasmic reticulum calcium
ATPase 2*
ER calcium-homeostasis ATP2A2
Wolframin ER calcium-homeostasis WFS1
Isoform long (1) of sodium/potassium-transporting ATPase
subunit α-1*
Sodium/potassium pump catalytic
subunit
ATP1A1
LanC-like protein 1 G-Protein-coupled receptor-signalling,
binds GSH
LANCL1
Microsomal glutathione S-transferase 3* GSH metabolism, peroxidase activity MGST1
Multidrug resistance protein 1* ATPase ABCB1
Isoform 2 of vacuolar-type proton ATPase 116 kDa subunit a
isoform 1
Transferrin recycling, iron homeostasis ATP6V0A1
Vacuolar-type proton ATPase 16 kDa proteolipid subunit Transferrin recycling, iron
homeostasis, pore subunit
ATP6V0C
Vacuolar-type proton ATPase catalytic subunit A* Vacuolar ATPase, transferrin
recycling, iron homeostasis
ATP6V1A
Vacuolar-type proton ATPase subunit d 1 Vacuolar ATPase, transferrin
recycling, iron homeostasis
ATP6V0D1
MITOCHONDRIAL RESPIRATION
CDGSH iron-sulfur domain-containing protein 1* Electron transport chain, oxidative
phosphorylation
CISD1
Cytochrome c oxidase subunit 5A, mitochondrial* Electron transport chain, cytochrome
C oxidase complex IV
COX5A
Cytochrome c oxidase subunit 5B, mitochondrial* Electron transport chain, cytochrome
C oxidase complex IV
COX5B
Cytochrome c oxidase subunit 6C Electron transport chain, cytochrome
C oxidase complex IV
COX6C
Cytochrome c oxidase subunit 7a polypeptide 2 (liver) precursor Electron transport chain, cytochrome
C oxidase complex IV
COX7A
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NUCLEO-CYTOPLASMIC TRANSPORT
Isoform 1 of nucleoporin NDC1 NPC anchoring between nuclear
envelope and soluble NUPs
NDC1
Importin subunit ß-1* Nuclear protein import via NPC,
nuclear localisation signal receptor
KPNB1
Isoform 1 of importin-5* Nuclear protein import via NPC,
nuclear localisation signal receptor
IPO5
GTP-binding nuclear protein Ran* Nucleo-cytoplasmic import, RNA
export, mitotic spindle-formation
RAN
Isoform 1 of exportin-2 Importin α re-export after cargo import CSE1L
Isoform A1-B of heterogeneous nuclear ribonucleoprotein A1* PolyA-mRNA export from nucleus HNRNPA1
Isoform short of heterogeneous nuclear ribonucleoprotein U* Nucleotide-binding, mRNA export HNRNPU
MITOCHONDRIAL TRANSPORT
Isoform 1 of mitochondrial import receptor subunit TOM40
homologue*
Mitochondrial precursor protein import TOM40
Mitochondrial import receptor subunit TOM22 homologue Mitochondrial precursor protein import TOM22
Mitochondrial carrier homologue 2 Induces mitochondrial de-polarisation MTCH2
Sideroflexin-1 Iron ion-transport in/out of
mitochondria
SFXN1
OTHER TRANSPORT
Ras-related protein Rab-10* GOLGI-membrane, ER dynamics,
phospholipid synthesis
RAB10
Ras-related protein Rab-11A* GOLGI-membrane, cytokinesis RAB11A
Ras-related protein Rab-1B* ER-GOLGI transport RAB1B
Ras-related protein Rab-2A* ER-GOLGI transport RAB2A
Ras-related protein Rab-3B Vesicular transport RAB3B
Ras-related protein Ral-A* Cytokinesis RALA
CILIA TRANSPORT
T-complex protein 1 subunit beta Chaperone, T-complex protein 1 ring
complex, cilia vesicle transport
CCT2
T-complex protein 1 subunit delta* Chaperone,cilia vesicle transport CCT4
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CILIA TRANSPORT
T-complex protein 1 subunit epsilon Chaperone,cilia vesicle transport CCT5
T-complex protein 1 subunit eta isoform d Chaperone,cilia vesicle transport CCT7
T-complex protein 1 subunit gamma isoform b* Chaperone,cilia vesicle transport CCT3
T-complex protein 1 subunit zeta Chaperone,cilia vesicle transport CCT6A
STRUCTURE
Coiled-coil-helix-coiled-coil-helix domain-containing protein 3,
mitochondrial*
Mitochondrial contact site complex,
mitochondrial cristae structure
CHCHD3
Fascin Actin bundle formation FSCN1
Filaggrin* Keratin intermediate filaments FLG
Isoform 1 of surfeit locus protein 4* GOLGI-organisation SURF4
Isoform ß-1A of integrin ß-1* Cell adhesion, cytokinesis ITGB1
Isoform DPI of desmoplakin* Desmosomes DSP
Keratin, type II cuticular Hb4 Universal signalling pathways KRT84
Keratin, type II cytoskeletal 3* Universal signalling pathways KRT3
Keratin, type II cytoskeletal 6B* Universal signalling pathways KRT6B
Keratin, type II cytoskeletal 6C* Universal signalling pathways KRT6C
MARCKS-related protein Actin cytoskeleton formation MARCKSL1
Myristoylated alanine-rich C-kinase substrate Actin-cross-linking MARCKS
Whole cell lysates of GFP and GFP-ALADIN expressing NCI-H295R cells were used for co-immunoprecipitation (co-IP). Proteins
not found in two independent GFP control co-IPs but found in all three independent GFP-ALADIN co-IPs are listed here. Proteins
are grouped according to their biological function or cellular role using UniProt database. Proteins with an asterisk were identified
simultaneously by GFP-ALADIN co-IP and by co-IP of endogenous ALADIN. Those in bold with an asterisk were found in none of
the controls of both expression models. Proteins in italic were detected as another isoform or protein from the same group in co-IP
of endogenous ALADIN.
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Table 21 – Functional classification of proteins identified by mass spectrometry analyses after co-
immunoprecipitation of endogenous ALADIN verified by proteins found at least once in exogenous
GFP-ALADIN co-IP.
PROTEIN METABOLISM GENE
LIPID METABOLISM/STEROIDOGENESIS
Isoform 1 of acylglycerol kinase, mitochondrial Lipid and glycerolipid metabolism AGK
Isoform 1 of NADH-cytochrome b5 reductase 3 CYP P450 regulation CYB5R3
Progesterone receptor membrane component 2* CYP P450 regulation PGRMC2
PROTEIN PROCESSING
Cathepsin D Lysosomal acid protease CTSD
Isoform 1 of serpin B3 Protease inhibitor SERPINB3
Isoform 1 of translocon-associated protein subunit α ER translocon complex SSR1
Isoform LAMP-2A of Lysosome-associated membrane
glycoprotein 2
Lysosomal metabolism LAMP2
Protein ERGIC-53 Protein recycling and sorting,
mannose-specific
LMAN1
Translocon-associated protein subunit delta precursor ER translocon complex SSR4
OTHER PATHWAYS
14-3-3 protein zeta/delta Universal signalling pathways YWHAZ
Isoform 2 of sarcoplasmic/endoplasmic reticulum calcium
ATPase 2
ER calcium-homeostasis ATP2A2
Isoform long (1) of sodium/potassium-transporting ATPase
subunit α-1
Sodium/potassium pump catalytic
subunit
ATP1A1
MITOCHONDRIAL RESPIRATION
CDGSH iron-sulfur domain-containing protein 2 Electron transport chain, oxidative
phosphorylation
CISD2
NUCLEO-CYTOPLASMIC TRANSPORT
Isoform 1 of importin-5 Nuclear protein import via NPC,
nuclear localisation signal receptor
IPO5
Whole cell lysates of NCI-H295R wild-type cells were used for co-immunoprecipitation (co-IP). Proteins not found in the mouse
normal IgG control co-IP but found in the ALADIN co-IP were compared to those found in the GFP-ALADIN co-IP (Table 20). Those
which were found in both co-IP models (at least once) and in none of the controls are listed here. Proteins are grouped according
to their biological function or cellular role using UniProt database. Proteins in italic were detected as another isoform or protein
from the same group in the GFP-ALADIN co-IP.
In co-IP conducted with whole cell lysates of NCI-H295R cells stably over-expressing the
GFP-ALADIN fusion protein 92 proteins not found in specific controls but in all three independent
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experiments were detected (Table 20). Distinct proteins involved in the nucleo-cytoplasmic
import of proteins and export of mRNA through NPCs were identified in the experiments. Among
these were the nucleoporin NDC1, importin subunit ß-1, importin-5, GTP-binding nuclear pro-
tein Ran, exportin-2, heterogeneous nuclear ribonucleoprotein A1 and heterogeneous nuclear
ribonucleoprotein U (HNRNPA1 and U). Well-known mitochondrial TOM (mitochondrial import
receptor subunit TOM40 and mitochondrial import receptor subunit TOM22) were found. Sev-
eral proteins or precursor polypeptides involved in different aerobic metabolism pathways (gly-
colysis, citric acid cycle (CAC), oxidative respiration chain) precipitated with ALADIN. Many of
these proteins have mitochondrial destination and/or origin and are nuclear-encoded. Many
glycolytic proteins of the cytosol feeding pyruvate into the mitochondrial TAC were recognised.
Main transporters (tricarboxylate transport protein and mitochondrial 2-oxoglutarate/malate car-
rier protein) and players of the CAC (2-oxoglutarate dehydrogenase, succinate dehydrogenase
andmalate dehydrogenase) impact on the mitochondrial respiration chain. Of this mitochondrial
electron transport chain cytochrome c oxidase subunit 5A, 5B, 6C and 7A precursor; all are
components of cytochrome C oxidase complex IV, were found. In addition, some proteins
involved in cholesterol synthesis and lipogenesis were identified. Concerning ALADIN being
involved in impairment of steroidogenesis, POR (not in Table 20 or 21) and PGRMC2 of the
proteomic analyses were of interest.
Reviewing proteins identified after co-IP using whole cell lysates of NCI-H295R wild-type
cells (and not found in the specific control experiment) with those detected in the GFP-ALADIN
co-IP (found at least once) cut down the total sum of possible interacting proteins to one sixth
(14 proteins) (Table 21). Proteins distinct for regulating lipogenesis or steroidogenesis were
acylglycerol kinase, NADH-cytochrome b5 reductase and PGRMC2. Several proteins involved
in protein maturation or processing could be found; among those were proteins of the translocon
complex in the ER membrane responsible for translocation-coupled translation: translocon-
associated protein (TRAP) subunit α (SSR1) and TRAP subunit delta (SSR4). The nucleoporin
NDC1 shown to interact with ALADIN (Kind et al., 2009; Yamazumi et al., 2009) could not be
reproduced in endogenous ALADIN co-IP, but the nuclear localisation receptor importin-5 could
be identified. Subunits of two specific ATPases, the first anchored within the ER membrane
(sarcoplasmic/endoplasmic reticulum calcium ATPase 2) and the second integrated within the
cell membrane (sodium/potassium-transporting ATPase), were repeatedly found.
4.6 ALADIN-dependent alteration in steroidogenesis requires an interactionwith
microsomal CYP P450 enzymes
4.6.1 PGRMC2 and POR precipitate with ALADIN in an exogenous and endogenous
adrenal cell expression model
Proteins simultaneously identified in GFP-ALADIN co-IP and co-IP of endogenous ALADIN
implying a specific connection to adrenocortical steroidogenesis were POR and PGRMC2 (Fig-
ure 27). Both are microsomal integral membrane proteins acting as regulators of several differ-
ent CYP P450 enzymes; the first one extensively studied, the latter barely known. Even though
POR was found in mass spectrometry to a small extent also in the co-IP negative controls
it was mainly focussed on the protein since recent results showed a possible interaction be-
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tween ALADIN and POR (Jühlen et al., 2015). Exclusive unique peptides of ALADIN, POR and
PGRMC2 detected in tandem mass spectrometry after GFP-ALADIN and endogenous ALADIN
co-IP are summarised in Figure 27. In the exogenous expression model sufficient ALADIN
peptides could be identified, the analysis of endogenous ALADIN co-IP resulted in less detected
peptides. Despite distinct methodological optimisation procedures using different protocols and
antibodies, endogenous ALADIN co-IP had a low yield and measurement using tandem mass
spectrometry was more difficult to process. Nevertheless, these results are presented here as
well.
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Figure 27 – Identified exclusive unique peptides of ALADIN, cytochrome P450 oxidoreductase and
progesterone receptor membrane compartment 2.
Identified exclusive unique peptides (yellow) (number of different amino acid sequences, regardless of any modification, that are
associated only with this protein) of cytochrome P450 oxidoreductase, progesterone receptor membrane compartment 2 and
ALADIN after co-immunoprecipitation of whole cell lysates of GFP-ALADIN over-expressing (A) and of wild-type NCI-H295R cells
(B). Peptide modifications are marked in green (oxidation of methionine (M)).
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In Figure 28 A Western Blot verifications of positive POR binding in the GFP-ALADIN co-
IP and co-IP of endogenous ALADIN is seen. Positiv PGRMC2 binding in the GFP-ALADIN
co-IP is shown in Figure 28 B. In co-IP of endogenous ALADIN bound antibodies to the beads
were revealed on Western Blot: light chains appeared at the size of 25 kDa disturbing efficient
PGRMC2 verification at 26 kDa due to much background. This result is not shown here. Bound
fractions of co-IPs were conducted for tandem mass spectrometry proteomic analyses as de-
scribed before. The most minimal level of POR unique peptides was detected once of three
in the specific negative control of GFP-ALADIN co-IP (two unique peptides) and five unique
peptides were found in the specific negative control of endogenous ALADIN co-IP (Figure 27).
This result could not be shown on Western Blot level where the negative controls remained
empty for POR protein (Figure 28 A). The experiments were repeated three times.
Figure 28 – Western Blot of bound fractions after GFP and ALADIN co-IP.
Whole cell lysates of GFP-ALADIN and GFP as negative control over-expressing NCI-H295R cells were prepared for GFP co-
immunoprecipitation (co-IP).Whole cell lysates of NCI-H295Rwild-type cells were prepared for ALADIN co-IP. Amousemonoclonal
antibody against ALADIN and normal mouse IgGs as negative control were used for ALADIN co-IP. Primary antibodies against
cytochrome P450 oxidoreductase (POR) (A) and progesterone receptor membrane compartment 2 (PGRMC2) (B) were used in
Western Blots. POR and PGRMC2 were found in each specific bound fraction implying possible interaction with ALADIN. No POR
and PGRMC2 were detectable in the fractions of the negative controls.
4.6.2 Immunofluorescent localisation of POR in adrenal cells
Further evidence of suggested interaction and communication should be given after immuno-
fluorescent staining of ALADIN and POR in adrenal NCI-H295R cells. Primary antibodies
against ALADIN and POR were proceeded for immunostaining. Secondary goat anti-mouse
tagged with alexa fluor 555 (staining ALADIN) and anti-rabbit IgGs tagged with alexa fluor 488
(staining POR) were applied. Immunofluorescent staining of the NUP ALADIN appeared at the
nuclear envelope at the proximity of NPCs. Themicrosomal POR localised to the central ER and
to the perinuclear space between nuclear envelope and ER. An overlay of both immunostainings
revealed co-localisation of ALADIN with POR at the perinuclear space (Figure 29) (n=3).
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Figure 29 – Immunofluorescent staining of ALADIN and cytochrome P450 oxidoreductase in NCI-H295R
wild-type cells.
Primary antibodies against ALADIN and cytochrome P450 oxidoreductase (POR), and secondary antibodies alexa fluor 555 goat
anti-mouse IgG (ALADIN, red) and alexa fluor 488 goat anti-rabbit IgG (POR, green) were used for immunofluorescence. Nuclei
were stained with DAPI (blue). Overlays are presented in the last column presenting co-localisation of ALADIN with POR at the
perinuclear space.
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5 Discussion
5.1 Role of ALADIN in human adrenocortical cells for oxidative stress response
and steroidogenesis
Primarily in the first part of this work, the cellular role of ALADIN was investigated by creating
two experimental expression systems using the human adrenocortical carcinoma cell line NCI-
H295R1-TR that resembles the glucocorticoid producing adrenal zona fasciculata (Wang et
al., 2012). These cells were successfully transformed to either over-express or down-regulate
ALADIN by a doxycycline-inducible stable expression of either AAAS-shRNA (AAAS down-
regulation) or AAAS-mRNA (AAAS over-expression).
In this study it is successfully demonstrated that AAAS knock-down firstly induces a sig-
nificant down-regulation of genes coding for type II microsomal CYP enzymes involved in the
glucocorticoid and androgen pathways of steroidogenesis, CYP17A1 and CYP21A2, and of
the gene coding for their electron donor enzyme POR. Secondly, it is revealed that the func-
tional output of these enzymes, i.e. precursor metabolites of the glucocorticoid and androgen
pathways, was markedly decreased in ALADIN knock-down cells.
In triple A patients adrenal insufficiency may appear later in life than the other two symptoms
and its development is gradually (Milenkovic et al., 2010). Glucocorticoid and androgen pro-
duction is affected, consistent with the presented in vitro results where production of precursors
involved in these pathways (17OHP, 11-deoxycortisol and androstenedione) was impaired. Fif-
teen percent of patients however show a deficiency in mineralocorticoid production (Clark and
Weber, 1998; Tsigos, 1999). Precursor metabolites of the mineralocorticoid pathway (DOC)
were not impaired in the experiments of this study. Mitochondrial aldosterone synthase encoded
by CYP11B2 exhibits 11ß-hydroxylase activity beside its activity to catalyse aldosterone from
corticosterone by 18-hydroxylation. 11ß-hydroxylase activity is expressed by a closely related
mitochondrial enzyme CYP11B1 in order to produce cortisol from 11-deoxycortisol (Kawamoto
et al., 1992). Furthermore it was shown that CYP11B2 exhibits some activity to hydroxylate
11-deoxycortisol (Kawamoto et al., 1992; Bureik et al., 2002). Thus, it can be assumed that 11-
deoxycortisol can serve as a substrate for aldosterone production. The relative preservation of
mineralocorticoid production in triple A patients resembles the lower production of aldosterone
compared to cortisol. This may save the zona glomerulosa from cell degeneration as it is seen
for the other zones (Clark and Weber, 1998).
Even though Prasad et al. already provided some evidence that lentivirally transduced
ALADIN-deficient adrenal cells show an alteration in steroidogenesis due to a decrease of
expression of StAR and CYP11B1 (Prasad et al., 2013), in this work stable transfection for
AAAS knock-down (and over-expression) was employed and the effects on steroidogenic en-
zyme expression and steroid production comprehensively investigated. In this work, by using
tandemmass spectrometry for multiple steroid identification and quantitation strong evidence for
a significant functional impairment of the glucocorticoid and androgenic pathways in ALADIN-
deficient cells is provided. Our findings lead further to the exact mechanism how ALADIN
deficiency affects steroidogenesis and elucidates more details about the pathogenesis in triple A
syndrome. These results therefore significantly add to the understanding of the role of ALADIN
for adrenal steroidogenesis.
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Many of the results are demonstrated in the partialAAAS knock-down state, i.e. the doxycycline-
uninduced state in which too little repressor is produced to efficiently block AAAS-shRNA ex-
pression leading to a premature AAAS knock-down. Nevertheless, the amount of AAAS-shRNA
produced is enough to silence partly AAAS gene expression and to exert a pathogenic pheno-
type in the adrenal cells. Adenoviral transduction in primary bovine adrenocortical cells has
been shown to result in the impairment of steroidogenesis and alteration of cell morphology
(Alesci et al., 2002). With regard to human adrenocortical cells Matkovic et al. could show that
adenoviral infection leads to alteration in steroidogenesis, presumably not due to viral transgene
expression but rather due to viral structure encounter (Matkovic et al., 2009). One can therefore
assume that the discrepancies in the findings between Prasad et al. and this work lie primarily
in the alternative cell model (transduction and stable transfection) and to some extent in the
experimental sample sizes especially for steroid analyses. Additionally, the zona fasciculata
sub-strain 1 of NCI-H295R cells (Wang et al., 2012) which resembles one of the zones most
degenerated in triple A patients (Clark and Weber, 1998) is different from the cells used by
Prasad and colleagues.
It was also ascertained that afterAAAS knock-down in NCI-H295R1-TR cells not only cellular
NADPH and GSH/GSSG levels were significantly decreased under oxidative stress using
paraquat but also that the concentration of cellular hydrogen peroxide was elevated. GSR
expression was not altered under basal conditions suggesting that the increase in sensitivity
to oxidative stress in these cells was not the result of low GSR expression. These findings
imply that ALADIN knock-down cells have an altered redox homeostasis and, hence, are more
sensitive to oxidative stress (Figure 30).
In order to further address the involvement of ALADIN in the oxidative stress response the
impairment of the nuclear import of proteins that protect the nucleus against ROS was analysed.
The nuclear import of APTX, LIG1 and FTH1 was markedly decreased after ALADIN depletion.
It can therefore be concluded as previously shown in fibroblast cells deriving from triple A
syndrome patients (Kind et al., 2010; Storr et al., 2009; Hirano et al., 2006) that ALADIN is
involved in oxidative stress responses and import of these proteins also in adrenocortical cells.
In addition, it was recently observed that fibroblast cells of triple A patients show an altered
down-regulation or induction of genes associated with oxidative stress and antioxidant defence
(Koehler et al., 2013). APTX and DNA ligases work concomitantly together in order to initiate
and repair DNA in multiple pathways and upon various deleterious factors, especially ROS-
mediated damage (Rass et al., 2007). Neurological disorders (early-onset ataxia with oculomo-
tor apraxia and hypoalbuminemia, MIM #208920) caused by mutations in APTX are probably
caused by accumulation of unrepaired DNA strand breaks resulting from abortive DNA ligation,
especially generated by oxidation (Rass et al., 2007; Ahel et al., 2006). Another possibility
of abortive DNA ligation (including LIG1) is during ribonucleotide excision repair. It has been
shown that adenylated RNA-DNA lesions are resolved by APTX and that accumulation of these
lesions is associated with neurologic diseases (Tumbale et al., 2014).
Triple A syndrome is commonly associated with a variety of neurologic impairments, pre-
sumably due to an increasing number of RNA-DNA lesions in patients’ neurons. APTX and
LIG1 both contain a nuclear localisation signal and are thought to be translocated into the
nucleus by a karyopherin-α/β-mediated pathway through NPCs. Hirano et al. presented that
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nuclear import of APTX and LIG1 is impaired when treating patient fibroblasts and control cells
with L-buthionine-(S,R)-sulfoximine (BSO), a glutathione-depleting agent, but single-stranded
DNA breaks increased only in patient cells (Hirano et al., 2006). Increased oxidative stress by
BSO seems to intensify nuclear import impairment in patient fibroblasts seen by accumulation
of single-stranded DNA breaks. These findings in patient fibroblasts are now confirmed by
our results in ALADIN knock-down adrenal cells which were also depleted of GSH and show
impaired nuclear import of APTX and LIG1.
Figure 30 – Increase of cellular susceptibility to oxidative stress afterAAAS knock-down in NCI-H295R1-
TR.
Deprivation of ALADIN in human adrenocortical cells leads to decreased levels of NADPH and concomitantly affects the buffer
amount of reduced glutathione (GSH) and increases hydrogen peroxide (H2O2). GSSG, oxidised glutathione disulphide. GPX,
glutathione peroxidase. GSR, glutathione reductase (Jühlen et al., 2015).
InAAAS over-expressing cells, neither steroidogenic enzyme expression nor steroid produc-
tion was altered. Surprisingly, similar to ALADIN deprivation, over-expressing cells showed a
significant impairment of cell viability and GSH/GSSG ratio under oxidative stress, but cellular
H2O2 concentration was not increased. In addition it is presented that over-expressing cells
have a decreased expression of GSR which explains the decreased GSH/GSSG ratio.
These results suggest that AAAS over-expression cells do not have an impaired redox po-
tential and are able to detoxify an increased level of ROS after paraquat treatment in contrast to
AAAS knock-down cells. In addition, it explains the finding that AAAS over-expression cells do
not show an alteration in steroidogenesis but rather behave like control cells. The impaired cell
viability and decreased expression of GSR may be caused by cell stress due to an increased
ALADIN protein synthesis and significant accumulation in the cytosol and ER.
Cellular ER stress has been recently reported to cause increased protein folding-stress.
Initial protein maturation takes place at the ER and is of importance of proper protein folding.
Increased protein synthesis and folding, especially in specialised secretory cells, introduces
a high level of stress and a particular challenge for the cell. If the ER machinery is working
over-strained an excess of synthesised proteins will be sensed causing a stop of translation,
ultimately leading to cell death (Hetz, 2012). I therefore hypothesise that this phenomenon
accounts for our AAAS over-expressing cells.
AAAS over-expressing cells did not show any change in nuclear import of APTX or LIG1. In
addition, the import of FTH1 was significantly decreased after AAAS over-expression. These
results together with the ALADIN knock-down results confirm the previously reported finding
that ALADIN is involved in the nuclear import of FTH1 (Storr et al., 2009).
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FTH1 is an iron chelator and its intrinsic ferroxidase activity is an important player in the
cellular antioxidant defence system by converting ferrous iron to its ferric storage form which
can act in the Fenton reaction as a ROS scavenger. FTH1 is shown to have transcriptional
regulatory activity which explains its translocation to the nucleus besides protecting the DNA
fromROS. Regarding its nuclear import, it is known that FTH1 enters the nucleus through NPCs,
but no obvious nuclear localisation signal has been found so far. It is rather thought to be shuttled
by a chaperon molecule to the NPC and into the nucleus (Misaggi et al., 2014; Thompson et
al., 2002; Alkhateeb and Connor, 2010). In corneal epithelial cells it was presented that FTH1
not passively diffuses into the nucleus but is rather shuttled by a chaperon molecule, called
ferritoid. This molecule seems to be highly specific for this cell type (Cai et al., 2008; Cai and
Linsenmayer, 2001).
In this study it is presented that AAAS over-expression leads to a significant accumulation
of ALADIN in the cytoplasm; most likely due to a lack of binding sites of ALADIN at the nuclear
pore complexes. Consequently, mislocalisation of ALADIN in the cytoplasm leads to a decrease
of nuclear import and subsequent retention of FTH1 in the cytoplasm. After treating ALADIN
knock-down and over-expression cells with paraquat for 24 h an increase of nuclear import of
FTH1 was observed. However, this import was significant diminished in the over-expression
model in comparison to paraquat treated control cells. In the knock-down model this effect was
not obvious, probably due to an insufficient total loss of ALADIN at the nuclear pore. Thus, it is
assumed here that FTH1 is withheld in the cytoplasm by ALADIN in the over-expression cells.
It still remains to be clarified how FTH1 is translocated into the nucleus and how this protein
interacts with ALADIN.
As a conclusion for the first part of this work, the results of the knock-down experiments in
the human cell line NCI-H295R1 are in accordance with the pathology in triple A syndrome
patients. They show an alteration in adrenal steroidogenesis, especially the glucocorticoid and
androgenic pathways, and an impairment in the cellular response to oxidative stress.
No such adrenal phenotype has so far been shown in AAAS knock-out mice (Huebner et
al., 2006). Mice predominantly have a zona glomerulosa, the aldosterone producing part of
the adrenal cortex which seems to escape cellular damage by ALADIN deprivation (Clark and
Weber, 1998; Huebner et al., 2006). The presented results suggest that alteration in adrenal
steroidogenesis in humans through POR is accompanied by a defective redox potential and
homeostasis due to ALADIN deficiency which is more elucidated in the second part of this
work.
The presence of ALADIN seems to be of high significance for detoxification of ROS in
adrenocortical cells and puts weight on the genuine susceptibility of this organ to oxidative
stress. This study shows that these processes affect adrenal cells and are likely to be causally
linked to the adrenal phenotype in triple A syndrome patients. It merits further research if
ALADIN deficiency preferentially affects cell-type specific transport and damage, because, as
seen in classic triple A syndrome patients, mainly cells of the adrenal cortex and of the nervous
system are damaged. It is recently investigated by Carvalhal and colleagues that ALADIN is
involved in Aurora A-kinase-dependent cell division (personal communication Sara Carvalhal
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et al, Dundee, 2015). Therefore, it can be assumed that cells damaged in triple A syndrome not
only have a unique metabolism but also a specific type of cell division.
In addition, a new role for the glucocorticoid receptor (GR), belonging to the nuclear hor-
mone receptor superfamily, has been established. Ligand-binding to the quiescent cytosolic
GR induces transformation, translocation in the nucleus and regulation of DNA transcription
leading to altered metabolism, immunity and cell fate. Besides these tasks the GR has been
discovered to co-ordinate mitotic progression and chromosome segregation by aggregating to
mitotic spindles, interestingly dependent on Aurora A. This action does neither require ligand-
binding nor transcriptional regulation (Matthews et al., 2015). Based on these recent results, the
role of ALADIN in mitosis awaits further studies and may add to the pathogenetic mechanisms
in triple A syndrome.
5.2 Involvement of ALADIN in translocation of specific nuclear-encoded mito-
chondrial precursors through the nuclear pore complex
In the second part of this study co-IP analyses of two ALADIN expression models wild-type
ALADIN and GFP-ALADIN over-expression using NCI-H295R adrenal cells followed by mass
spectrometry provided an experimental approach to aim for new interaction partners of ALADIN
and for elucidation of further pathways involved in the pathogenesis of triple A syndrome.
Astonishingly in co-IP with lysates of GFP-ALADIN-expressing NCI-H295R cells followed by
mass spectrometry, a huge part of those proteins being identified were proteins of mitochon-
drial destination or origin. In addition, two specific heterogeneous nuclear ribonucleoproteins,
HNRNPA1 and U, precipitated with ALADIN. These chaperone proteins are responsible for
precursor (pre-) mRNA processing, metabolism and mature mRNA nuclear export.
The small nuclear GTPase Ran was also detected in co-IP with lysates of GFP-ALADIN-
expressing cells. Ran cycling between bound GTP in the nucleus and GDP in the cytoplasm
adjusts import and export between nucleus and cytosol. Ran-GTP carries a specific cargo
containing a nuclear export signal bound to a receptor (e.g. mRNA coated with a myriad of
proteins forming the messenger ribonucleoprotein (mRNP) particle) and is transferred through
the NPC to the cytosol. Ran-GDP releases its cargo on the cytoplasmic site of the NPC and
GTP is hydrolysed to GDP by a Ran-GTP-activating protein (Figure 31). Some pathways for
RNA export through NPCs are described in the following. Many of those pathways use Ran
cycling as the shuttle mechanism (Cole and Scarcelli, 2006; Katahira, 2015; Okamura et al.,
2015).
Pre-mRNA undergoes splicing, 5’-capping and cleavage/polyadenylation at the 3’-end be-
fore being exported as mature mRNA from the nucleus. Association with factors involved in
nuclear export is conducted during transcription and pre-mRNA processing, ultimately forming
the mRNP particle. Functional and mature mRNA is then encountered by the transcription
machinery in the cytoplasm (Katahira, 2015). Small non-coding RNAs (transfer RNA and micro
RNA) are exported from the nucleus by proteins of the importin/karyopherin-β family comprising
the prototypical transport receptors. This mechanism uses Ran cycling (Cole and Scarcelli,
2006; Katahira, 2015).
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Figure 31 – The Ran cycle.
Depending on its subcellular localisation Ran cycles between GTP- and GDP-bound states. During import (left) karyopherins
(importins) in the cytoplasm bind to cargoes containing a nuclear localisation signal and are transferred through nuclear pore
complexes to the nucleus. Ran-GTP binds to importins and releases the cargo. The Ran-GTP-importin complex is then recycled
to the cytoplasm where it is disrupted after GTP hydrolysis by a Ran-GTP-activating protein. During export (right) nuclear Ran-GTP
stabilised by RanGEF binds a cargo containing a nuclear export signal bound to exportins and is translocated through the nuclear
pore complex to the cytosol. Ran-GDP releases its cargo on the cytoplasmic site and GTP is hydrolysed to GDP. D, Ran-GDP. T,
Ran-GTP. β-kap, importin/karyopherin-β. RanGEF, Ran guanine exchange factor (Rout and Aitchison, 2001).
Nuclear export of mRNA does not comprise importin/karyopherin-β proteins but rather an
evolutionarily conserved heterodimeric transport receptor Tap-p15. In order to bind and to direct
to different mRNAs the conserved transcription-export complex and several serine-arginine rich
proteins associate with the transport receptor. Tap-p15 bound to its mRNA-cargo makes contact
with FG-repeats of distinct NUPs and upon escape to the cytoplasm dissociates from its cargo
in order to avoid re-entering of the mRNA into the nucleus (Cole and Scarcelli, 2006; Katahira,
2015). This pathway does not directly depend on Ran cycle, but p15 is shown to bind Ran-GTP
and is thought to assist export of other RNA and proteins (Black et al., 1999). Transport receptor
Tap-p15 co-ordinates bulk mRNA export but certain groups of mRNAs are exported via Crm1.
Crm1 belongs to the importin/karyopherin-β family and depends on adaptor proteins being
able to bind RNA. Export of nuclear RNA mediated by Crm1 involves Ran cycle (Okamura et
al., 2015). NUPs of the cytoplasmic filaments rich in FG-repeats are thought to be essentially
involved in mRNA export in yeast. In metazoa these NUPs are shown to have the same lo-
cation and are essentially thought to have the same function (NUP214, NUP88 and NUP358)
(Fahrenkrog, 2014; Cole and Scarcelli, 2006). Ran cycle is an essential player of RNA export
from the nucleus and is involved in a myriad of export mechanisms. In the GFP-ALADIN over-
expression model Ran, importin-5 and heterogeneous nuclear ribonucleoprotein A1 and U were
shown to co-precipitate with ALADIN. This highlights the assumption that ALADIN is involved
in the export of especially mRNA.
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Based on the fact that ALADIN seems to be involved in the export of mature mRNA from the
nucleus the finding of mitochondrial precursors like COX7A and succinate dehydrogenase pre-
cursor in co-IP with lysates of GFP-ALADIN-expressing cells raises the question of cytoplasmic
transport from the nucleus to the mitochondria of nuclear-encoded mRNA. There is evidence in
lower eukaryotes like Saccharomyces cerevisiae that nuclear-encoded mitochondrial products
are passed to the organelle either in form of nascent polypeptide-associated complexes (NACs)
or as RNP particles which are thought to be co-translationally transported. The first group is
synthesised in the cytoplasm prior mitochondrial import through TOM-translocase of the inner
mitochondrial membrane (TIM23) pathway. Mitochondrial precursor proteins are equipped with
a N-terminal mitochondrial targeting sequence rich in positively charged residues interacting
with the TOM-TIM23 pore carrying many negatively charged amino acids (Tarassov et al., 2007;
Ding et al., 2009).
Regarding the co-translational transport of mitochondrial products most studies in yeast
revealed that the mRNA is transported within the cytoplasm to the mitochondrial surface either
by passive diffusion or active transport occupied by the micro cytoskeleton or translocation
associated within the ER in a signal recognition particle (SRP)-dependent manner (Figure 32)
(Ding et al., 2009). SRP is a RNP complex binding early in the translation process and tar-
geting the mRNA-ribosome-nascent polypeptide chain to the ER. Recognition is achieved by
topogenic hydrophobic signals in the peptide precursor chain. A receptor associated with the
ER membrane, the SRP receptor, mediates targeting of the complex and induces binding of
the ribosome to the translocation channel (Sec61 complex). After docking of the complex to the
translocation channel the protein is secreted across or into the ER membrane (Figure 33) (Reid
and Nicchitta, 2015).
Figure 32 – Transport of nuclear-encoded mitochondrial mRNA in the cytoplasm.
The three different pathways are numbered. Nuclear-encoded mitochondrial mRNA exported through the nuclear pore complex
(NPC) is thought to be either transported by (1) free diffusion of ribonucleoprotein (RNP) particles to the mitochondrial surface,
(2) molecular motors on the cytoskeleton (microtubules) or (3) active transport along the endoplasmic reticulum (ER) (Ding et al.,
2009).
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Figure 33 – The model for translational compartmentalisation.
Cytosolic proteins which lack a topogenic signal at their N-terminus targeting them to the endoplasmic reticulum (ER) are translated
in the cytosol. Proteins encoded by mRNAs containing a signal peptide or a transmembrane domain at their N-terminus (secretory
or integral membrane proteins) are co-translationally targeted to the ER by the signal recognition particle (SRP) pathway and SRP
receptor in the ER membrane (Reid and Nicchitta, 2015, modified).
Fifty percent of mRNA encoding mitochondrial proteins are translated in the proximity of
mitochondria. Such mRNA is called mitochondrially localised mRNA (MLR). Those MLRs are
as well thought to be translocated via TOM-TIM23 pathway (Tarassov et al., 2007; Ding et al.,
2009). With MLR calculations in yeast using bioinformatics mRNAs targeted for mitochondria
have been divided into different groups: MLR class I localises to mitochondria (I-1 strictly and I-2
partly dependent on the translation regulatory protein Puf3p), class II localises to mitochondria
(Puf3p independent) and class III does not localise to mitochondria (Figure 34).
Figure 34 – Sub-classification of mitochondrially localised mRNA according to their Puf3p dependence
in yeast.
Mitochondrially localised mRNAs (MLRs) are distinguished in two main classes, class I and class II, by the presence or absence
of at least one pumilio family 3 (PUF3) motif in the mRNA 3’-UTR, respectively. Class I-1 is thought to depend solely on Puf3p for
their mitochondrial localisation and is highly sensitive for cycloheximide which is believed to solidify mRNA-ribosome complexes.
Class I-2 seems to depend also on other transacting factors besides Puf3p (here symbolised as question mark) (Saint-Georges et
al., 2008).
Puf3p belongs to the Pumilio family (PUF) and it is shown to bind as a trans-acting factor
to a consensus motif in 3’-UTR of mRNA encoding mitochondrial yeast products. Puf3p is a
mitochondrial RNA-binding protein at the cytosolic face of the outer mitochondrial membrane
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with multiple functions (Garcia-Rodriguez et al., 2007; Jackson et al., 2004; Gerber et al.,
2004). The protein seems to mediate transport and stability of a specific set of nuclear-encoded
mitochondrial mRNAs thereby affecting mitochondrial biogenesis (Saint-Georges et al., 2008).
In this study, structural proteins of mitochondrial respiration complex IV COX5A, 5B, 6C and
7A were shown to co-immunoprecipitate with ALADIN in lysates of human adrenocortical cells
expressing GFP-ALADIN. These nuclear-encoded mitochondrial proteins are non-MLRs (class
III). They are thought to be synthesised on cytosolic free ribosomes and precursor protein import
shall most likely occur through TOM-TIM23 pathway.
Additionally, identified components of the CAC among these 2-oxoglutarate dehydrogenase,
succinate dehydrogenase (mitochondrial respiration complex II) and malate dehydrogenase are
MLR class II, class I-2 and class III, respectively. 2-oxoglutarate and succinate dehydrogenase
are translated in the vicinity of mitochondria and mRNA translation is partly dependent on Puf3p
in the case of succinate dehydrogenase (Saint-Georges et al., 2008; Perocchi et al., 2006).
The result suggests that ALADIN, probably in an oligomeric protein complex, seems to
take part in the transport of nuclear-encoded mitochondrial proteins in either way; as NACs
(for all MLR class III) or co-translationally as RNP complex (class II and I). ALADIN is likely
to build large multimeric protein complexes due to its several WD repeats (Tullio-Pelet et al.,
2000; Rabut et al., 2004). Remarkably, precursor proteins of two identified proteins were found
in mass spectrometry analysis (COX7A and succinate dehydrogenase precursor); underlying
the suggestion that ALADIN takes part in the translocation of mitochondrial precursors. More
evidence that ALADIN is involved in the transport of nuclear-encoded mitochondrial proteins
is raised by the fact that several subunits of the mitochondrial TOM complex (TOM40, TOM22
and TOM70) and the ER membrane-associated TRAP subunit α (SSR1) were found after GFP-
ALADIN co-IP and mass spectrometry.
These findings emphasise the hypothesis that transport of nuclear-encoded mitochondrial
proteins may specifically involve ALADIN. NACs synthesised in the cytosol and RNP complexes
transported through the translocon channel are imported into the mitochondria through the TOM
complex (Tarassov et al., 2007; Ding et al., 2009). Furthermore, the glycolytic enzyme enolase-2
was shown to be a chaperone to facilitate tRNA import into mitochondria (Brandina et al., 2006;
Entelis et al., 2006). Enolase-1 co-precipitated with ALADIN in the GFP-ALADIN expression
model. This enzyme has not yet been shown to be involved in cytoplasmic RNA transport to
mitochondria, but it localises to the organelle in rat cardiomyocytes which suggests a possible
interaction (Gao et al., 2014).
In co-IP of endogenous ALADIN proteins of mitochondrial destination or origin could not be
verified to be simultaneously detected in both ALADIN expression models. The fusion protein in
the GFP-ALADIN over-expression model in NCI-H295R cells is not only localised to the nuclear
pore but also to the cytoplasm (data not shown). False localisation could lead to false positive
results or abolish real protein connections when looking for ALADIN-interacting proteins. In
order to verify results produced by co-IP with lysates of GFP-ALADIN expressing NCI-H295R
cells sepharose beads were coated with an antibody against ALADIN and co-IP with lysates of
NCI-H295R cells was conducted.
Since ALADIN is expressed at a very low level in the cell and exclusively at the NPC (eight
ALADIN proteins per NPC (Cronshaw et al., 2002)), co-IP of endogenous ALADIN was chal-
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lenging. This method was successfully established but in mass spectrometry remarkably less
ALADIN was detected compared to the GFP-ALADIN expression model. Thus, not all proteins
detected in GFP-ALADIN co-IP could be verified in endogenous co-IP. Detection especially of
proteins of mitochondrial destination could have been abolished in the wild-type model since
co-IP of ALADIN was not as efficient as in the GFP-ALADIN expression model.
The assumption that GFP-ALADIN co-IP would detect an increased number of false pos-
itive proteins could be raised but was tried to ruled out by repetition and reproduction of the
experiment. Only those proteins detected in all three co-IPs with lysates of GFP-ALADIN
expressing NCI-H295R cells were conducted for further analysis and grouped as a possible
positive match to look at. In GFP-ALADIN co-IP SSR1 is identified and SSR1 and SSR4 (TRAP
subunit delta) were both detected after co-IP of ALADIN. Both proteins closely associate with
the Sec61 translocation channel translocating nascent chains of secretory proteins across the
ER membrane into the lumen (Gorlich et al., 1990).
This supports the hypothesis that ALADIN is closely involved in targeting the nuclear ex-
ported mRNA-ribosome-nascent polypeptide chain to the ER. If and how ALADIN plays a role
in establishing nuclear mRNA targeting to the ER, shall be investigated in future research and
may further characterise the perhaps predominant function of ALADIN in cell metabolism.
5.3 ALADIN-dependent alteration in steroidogenesis postulates an interaction
with microsomal CYP P450 regulators
In wild-type ALADIN and GFP-ALADIN over-expression co-IP analyses followed by mass spec-
trometry POR was one of the proteins identified to interact with ALADIN. It seemed reasonable
to discover this possible interaction inmore detail because it is shown that deprivation of ALADIN
leads to impairment of glucocorticoid and androgenic steroidogenesis and of cytochrome P450
oxidoreductase (Jühlen et al., 2015).
Co-IP studies showed that ALADIN precipitated with the microsomal flavoprotein and in co-
localisation immunofluorescent studies both proteins appear at the same perinuclear ER. In
the GFP-ALADIN over-expression model POR co-precipitated with ALADIN. This result could
be shown after mass spectrometry analyses and on Western Blot. In order to verify results
produced by GFP-ALADIN co-IP, wild-type ALADIN co-IP was conducted. ALADIN is expressed
at very low levels in the cell and exclusively at the NPC (Cronshaw et al., 2002). This made
endogenous ALADIN co-IP challenging. The method was successfully established but in mass
spectrometry less ALADIN was detected compared to the GFP-ALADIN over-expressionmodel.
Nevertheless, POR could be efficiently reproduced as a potential interaction partner of ALADIN.
Negative controls for both co-IPs showed low levels of detected peptides exclusively belonging
to POR. This result could not be shown on Western Blot level since protein/peptide amounts of
POR in the negative control were either too low to be detected by antibody or this result was
unspecifically identified by mass spectrometry analyses.
All microsomal P450s need POR for their catalytic activity. The steroid output can be dimin-
ished even if the specific CYP P450 enzyme activity is unchanged (Fluck and Pandey, 2011).
This was shown in ALADIN-deficient cells where the steroid output and gene expression of
microsomal CYP17A1 and CYP21A2 hydroxylases was decreased accompanied by minimised
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POR gene expression (Jühlen et al., 2015). Interestingly, CYP21A2 hydroxylase was also de-
tected in mass spectrometry to co-precipitate with ALADIN after co-IP of endogenous ALADIN
(data not shown). This underlines the fact that POR might be a possible target for ALADIN-
dependent alteration in adrenal steroidogenesis.
CYP P450s are heme-containing enzymes metabolising endogenous compounds or xeno-
biotics. These enzymes are mainly localised to the membrane of the ER or at lower levels
to the inner mitochondrial membrane. Nevertheless, they have also been identified in other
sub-cellular compartments: at the outer nuclear membrane, in GOLGI subunits, at the plasma
membrane or in peroxisomes. Anchorage of CYP P450s to membranes is achieved by a
hydrophobic tail at the N-terminus; thereby exposing the catalytic domain and the rest of the
enzyme to the cytoplasm or the mitochondrial matrix.
Transcription of CYP P450 mRNAs is SRP-dependent and translation occurs on membrane-
free ribosomes with hydrophobic N-terminus acting as topogenic signal (Figure 33). Translation
is stopped by binding of the SRP and only resumed when the complex consisting of SRP, ribo-
some and nascent protein chain is bound to the SRP receptor anchored in the ER membrane.
Upon binding of the complex SRP is released and the growing polypeptide chain of the CYP
P450 enzyme is transferred through the Sec61 translocon complex into the ER. Translocation of
the polypeptide is immediately stopped when the N-terminus meets the translocation channel.
The remainder of the protein is in the following translated on the cytoplasmic site of the ER
membrane (Neve and Ingelman-Sundberg, 2008; Seliskar and Rozman, 2007).
The hydrophobic N-terminus of CYP P450s leading SRP-dependent translation of the pro-
tein has also been shown to be sufficient for ER retention mechanisms of the mature protein. In
addition, large immobile oligomeric complexes built of, for example POR and CY Pb5, were also
thought to be excluded from ER exit sites and consequently, lead to retention of the proteins
in the ER. Beside these hypotheses other possible mechanism exist resulting in retention in
the ER but the exact mechanism of restrict ER localisation of many CYP P450s remains to be
identified (Neve and Ingelman-Sundberg, 2008; Seliskar and Rozman, 2007).
Non-genomic, membrane-associated progesterone receptors (MAPRs) are also restricted to
the ER and are thought to regulate the activity of CYP P450 enzymes. The first identified MAPR,
PGRMC1, gained wide-spread attention (Falkenstein et al., 1996). PGRMC1 is a cytochrome-
related protein with several implications in cancer. In my work, PGRMC2 was shown to interact
with ALADIN in GFP-ALADIN co-IP studies and in co-IP of endogenous ALADIN followed by
application of mass spectrometry. The protein is mainly localised to the ER membrane, is the
second member of the MAPR family and barely investigated compared to its homologue brother
PGRMC1.
There is evidence that both MAPRs probably have emerged from a common gene (Wendler
and Wehling, 2013; Keator et al., 2012). PGRMC1 lies on the X-chromosome whereas the
gene for PGRMC2 resides on chromosome 4. Their protein structure is made up of a N-terminal
extracellular domain followed by a transmembrane region and a cytoplasmic domain. Despite
their close relation, there are differences in protein expression and function. Both proteins are
involved in regulation of ovarian follicle development and therefore imply a neuroendocrine func-
tion (Wendler and Wehling, 2013; Keator et al., 2012). Deficiency of either MAPRs decreases
the anti-apoptotic and/or anti-mitotic action of progesterone, although PGRMC2 seems to be
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important for anti-mitotic actions of the steroid. Furthermore, MAPRs exert some progesterone-
independent actions (Peluso et al., 2014). Depletion of either PGRMC1 or PGRMC2 leads to
increased entry into cell cycle. Both proteins localise to the mitotic spindle and seem to exploit
a distinct role during metaphase of mitosis by binding to each other, thereby suppressing entry
into cell cycle. This effect is thought to be synergistic and does not seem to be additive (Peluso
et al., 2014).
PGRMC2 is proven to act on mitosis and is recently shown by Griffin and co-workers to
interact with the cyclin-dependent kinase 11b (p58), a kinase regulating G0 to G1 transition in
mitosis. Interestingly, the expression of the MAPR was seen to be cell cycle-dependent with
reduced expression between G0 and G1. This event could facilitate entry into cell cycle by
releasing PGRMC2 inhibition (Griffin et al., 2014).
It is additionally known that PGRMC2 alters activity of CYP3A4 as possible electron donor,
and binds CYP21A2, most likely through its CY Pb5-similar heme-binding domain (Wendler and
Wehling, 2013; Albrecht et al., 2012). Up to now PGRMC2 shall await more investigations
besides its role as tumour suppressor, migration inhibitor and of note, activity regulator of CYP
P450 enzymes (Wendler and Wehling, 2013). ALADIN possibly interacts with the nuclear small
GTPase Ran. This enzyme is investigated not only to be involved in nucleo-cytoplasmic trans-
port but also exhibits a distinct role during mitosis (Clarke and Zhang, 2008). Cell-cycle control
can be postulated to be one common pathway of PGRMC2 and ALADIN. Further research is
warranted to elucidate the involvement of ALADIN in mitosis and meiosis.
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5.4 Conclusion
Increased sensitivity to oxidative stress, especially in the adrenal, is a significant hallmark of
the pathogenesis of triple A syndrome. In co-IP using an ALADIN over-expression model in the
human adrenocortical cell line NCI-H295R complexes of the mitochondrial respiration chain (IV
and II) and of the CAC were found. But ALADIN presumably does not localise to mitochondria
as shown for the cytoplasmic filament RANBP2/NUP358 thereby acting onmitochondrial energy
homeostasis (Aslanukov et al., 2006; Cho et al., 2007).
This implies that ALADIN co-ordinates the shuttle of nuclear-encoded mitochondrial proteins
exiting the nucleus through the NPC. Support of this hypothesis is provided in this work; not only
in the second division but also evidenced as secondary effects in the first part of the results,
seen as increased sensitivity to oxidative stress in adrenocortical carcinoma cells (Jühlen et
al., 2015). Attenuation of aerobic mitochondrial respiration through a deficient mRNA transport
pathway of either components of the respiration chain or of the CAC, that feeds to a great part in
mitochondrial respiration by donating NADH, ultimately leads to increased levels of oxidative
stress as seen in triple A patient fibroblasts and adrenocortical cells in vitro (Kind et al., 2010;
Prasad et al., 2013; Jühlen et al., 2015; Storr et al., 2009; Hirano et al., 2006).
Importantly, vacuolar acidification has also been coupled to mitochondrial respiration chain
by Perocchi and co-workers but the mechanism remains to be determined (Perocchi et al.,
2006). Vacuolar-type proton ATPase, an enzyme involved in vacuolar acidification by using
ATP and pumping protons in intracellular compartments, seems to be connected to ALADIN
as different subunits of this multi-complex enzyme co-precipitated with the nucleoporin in this
work. These findings on the exclusive task of ALADIN for the translocation of nuclear-encoded
mitochondrial precursors gives important insights in the distinct role of the nucleoporin and
deserves a huge degree of future investigations.
In the future it needs to be investigated how ALADIN affects the expression of POR and
why the nucleoporin co-localises with the microsomal flavoprotein at the perinuclear ER. Con-
clusively, the answer on this question can elucidate a significant role of ALADIN but merits
more research. SRP-dependent translation of nuclear-encoded mitochondrial precursors and
of microsomal-residing CYP P450s, is crucial for both protein processing and translocation.
Given the relationship between ALADIN and PGRMC2, POR is not the only microsomal
CYP P450 enzyme possibly interacting with ALADIN. There is first evidence that PGRMC2
is cytochrome-related and, like POR, acts as electron donor for specific CYP P450 (Wendler
and Wehling, 2013; Albrecht et al., 2012). As an integral ER membrane protein, PGRMC2
presumably also depends on translation involving SRP. The mechanism of SRP-dependent
targeting to the ER could be a hallmark of the involvement of ALADIN. Given the relationship
among ALADIN and SRP-dependent translation this mechanism would justify and explain glu-
cocorticoid insufficiency and mitochondrial dysfunction seen after ALADIN deprivation.
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6 Summary
Autosomal recessive triple A syndrome is caused by mutations in the AAAS gene encoding the
protein ALADIN. The disorder manifests with the triad of adrenocorticotropic hormone-resistant
adrenal insufficiency, achalasia of the stomach cardia and impaired tear production (alacrima) in
combination with progressive neurological impairment of the central, peripheral and autonomic
nervous systems. ALADIN is part of the nuclear pore complex acting as a scaffold nucleoporin.
In this work the role of ALADIN in the human adrenocortical tumour cell line NCI-H295R1 was
investigated. These cells were engineered to either over-express or down-regulate AAAS by
inducible stable transfection. Alterations in steroidogenic gene expression and functional conse-
quences were determined. In addition, the role of ALADIN on cell viability and oxidative stress
response was analysed. Using both the human adrenal NCI-H295R1-TR AAAS knock-down
and over-expression models the potential impairment of the nuclear import of aprataxin, DNA
ligase 1 and ferritin heavy chain 1 was investigated. For this YFP-specific vectors transiently
transfected into the cell lines were employed.
The findings indicate that AAAS knock-down induces a down-regulation of genes coding for
type II microsomal cytochrome P450 hydroxylases CYP17A1 and CYP21A2 and their electron
donor enzyme cytochrome P450 oxidoreductase, thereby decreasing biosynthesis of precursor
metabolites required for glucocorticoid and androgen production. Furthermore I demonstrate
that ALADIN deficiency leads to increased susceptibility to oxidative stress and alteration in
redox homeostasis after paraquat treatment. Finally, I show significantly impaired nuclear
import of DNA ligase 1, aprataxin and ferritin heavy chain 1 in ALADIN knock-down cells. I
conclude that down-regulating ALADIN results in decreased oxidative stress response leading
to alteration in steroidogenesis, highlighting the knock-down cell model as an important in vitro
tool for studying the adrenal phenotype in triple A syndrome.
In an approach to identify new interaction partners of ALADIN, co-immunoprecipitation fol-
lowed by proteome analyses using mass spectrometry was conducted in a GFP-ALADIN over-
expression model using the human adrenocortical tumor cell line NCI-H295R. These results
were verified in co-immunoprecipitation assays of endogenous ALADIN using NCI-H295R wild-
type cells. The results suggest a possible interaction between ALADIN and microsomal flavo-
protein cytochrome P450 oxidoreductase and progesterone receptor membrane compartment
2. Co-localisation analyses of these findings were done using immunofluorescence. The data
are suggestive for an involvement of ALADIN in the export of nuclear-encoded mitochondrial
proteins.
Regulation of adrenocortical steroidogenesis is complex and there is increasing evidence
that oxidative stress due to ROS accumulation and mitochondria are significantly involved.
Furthermore, there may be an important cross-talk between functional organelles comprising
nucleus, ER and mitochondria which presumably involves lipid metabolism. The goal of this
work was to elucidate the function of ALADIN for the cellular oxidative stress response and its
possible consequences for adrenocortical steroidogenesis in triple A syndrome patients.
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7 Zusammenfassung
Mutationen im AAAS Gen verursachen die autosomal rezessive Krankheit Triple-A-Syndrom.
AAAS kodiert das Nukleoporin ALADIN, welches Bestandteil des nukleären Porenkomplexes
ist. Phänotypische Charakteristika des Triple-A-Syndroms sind Nebennierenrinden-Insuffizienz,
Achalasie des unteren Speiseröhrenschließmuskels und eine fehlende Tränenproduktion (Ala-
krimie). Diese Symptome sind kombiniert mit progredienten neurologischen Störungen des
zentralen, peripheren und autonomen Nervensystems. In dieser Arbeit wurde die Rolle von
ALADIN in der humanen Karzinom-Zelllinie NCI-H295R1 untersucht. Diese Nebennierenrinden-
Zellen wurden stabil transfiziert und mit einem induzierbaren Expressionssystem modifiziert,
so dass sie AAAS entweder überexprimierten oder herunterregulierten. In NCI-H295R1-Zellen
wurden Veränderungen der Genexpression von Enzymen der Steroidogenese und funktionelle
Konsequenzen der Überexpression oder Herunterregulation von ALADIN gemessen. Des Wei-
teren wurde die Rolle von ALADIN auf die Zellviabilität und die Redox-Homöostase analysiert.
ALADIN überexprimierende und herunterregulierte Zellen wurden verwendet, um die potentielle
Behinderung des nukleären Imports von Proteinen zu untersuchen, welche den Zellkern gegen
oxidativen Stress schützen (z.B. Aprataxin, DNA-Ligase 1 und Ferritin Heavy Chain 1). Dazu
wurden YFP-spezifische Vektoren transient in diese Zellen gebracht.
Mit den Ergebnissen dieser Arbeit wurde gezeigt, dass die Herunterregulation von AAAS
eine Verminderung der Genexpression von CYP17A1 und CYP21A2 und deren Elektronen-
donor Cytochrom P450 Oxidoreduktase bewirken. Die Biosynthese der Vorläufermetabolite
von Kortisol und Aldosteron ist in diesen Zellen ebenfalls vermindert. Des Weiteren zeigen die
ALADIN-defizienten NCI-H295R1-Zellen eine erhöhte Sensitivität gegenüber oxidativem Stress
und eine veränderte Redox-Homöostase nach der Behandlung mit Paraquat. Darüber hinaus
konnte in dieser Studie auch gezeigt werden, dass herunterregulierte ALADIN NCI-H295R1-
Zellen einen verminderten Zellkernimport von Aprataxin, DNA-Ligase 1 und Ferritin heavy chain
1 besitzen. Aus diesen Ergebnissen kann geschlussfolgert werden, dass ALADIN-defiziente
Nebennierenzellen eine verminderte Stressantwort auf oxidativen Stress besitzen; dies führt
schlussendlich zu einer veränderten Steroidogenese. Das beschriebene ALADIN knock-down
Modell in NCI-H295R1-Zellen ist ein wichtiges in vitro Werkzeug, um die Pathogenese der
Nebennierenveränderungen im Triple-A-Syndrom zu erforschen.
Neue Interaktionspartner von ALADIN wurden mit Hilfe von Co-Immunpräzipitation gefolgt
von Proteom-Analysen durch Massenspektrometrie in einem GFP-ALADIN Überexpressions-
modell in NCI-H295R charakterisiert. Die Ergebnisse wurden durch Experimente auf endo-
genem Niveau in NCI-H295R-Wildtypzellen verifiziert. Mit diesen Daten wird in dieser Arbeit
erstmals eine Interaktion zwischen ALADIN und dem Flavoprotein Cytochrom P450 Oxidore-
duktase und Progesterone Receptor Membrane Compartment 2 nachgewiesen. Diese Ergeb-
nisse wurden mit Co-Lokalisierungsanalysen durch Immunfluoreszenzfärbung von ALADIN und
Cytochrome P450 Oxidoreduktase ergänzt. Außerdem gibt die Arbeit Hinweise darauf, dass
ALADIN als Nukleoporin an dem nuklearen Export mitochondrialer Vorläuferproteine beteiligt
ist.
Die Regulation der Steroidogenese in der Nebennierenrinde ist komplex und es existie-
ren zahlreiche Hinweise darauf, dass oxidativer Stress aufgrund der Ansammlung reaktiver
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Sauerstoffradikale und. dass die Mitochondrien involviert sind. Außerdem ist ein funktionelles
Zusammenspiel verschiedener Organellen, darunter Nukleus, ER und Mitochondrien, von gro-
ßer Bedeutung. Das Ziel dieser Arbeit war die Identifizierung der Funktion von ALADIN in der
zellulären oxidativen Stressantwort und die möglichen Konsequenzen für die Steroidogenese
in der Nebennierenrinden in Triple-A-Syndrom-Patienten.
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